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ABSTRACT OF THE DISSERTATION 
 
 
The Role of SRC Kinase in Estrogen Receptor-positive Breast Cancer Cell 
Proliferation and Tumor Growth 
 
By 
 
Christopher Arif Abdullah 
 
Doctor of Philosophy in Biomedical Sciences 
University of California, San Diego, 2017 
Professor Jean Y. J. Wang, Chair 
Professor Sara A. Courtneidge, Co-Chair 
 
 
Non-genomic estrogen (E2) signaling has previously been implicated in 
promoting E2-dependent proliferation, but the mechanism by which this occurs is not 
known. Here, we found a requirement for the protein tyrosine kinase, SRC, in cell 
cycle progression and proliferation in quiescent estrogen receptor (ER)-positive 
  xviii 
breast cancer cells stimulated with E2 in vitro. Using a SRC family kinase (SFK) 
inhibitor, SU11333, and shRNA mediated knockdown, we demonstrated that SRC, 
but not YES, is required for cell cycle progression and proliferation in vitro. Using the 
SRC/ABL selective kinase inhibitor, saracatinib, we also demonstrated that SFKs 
were required for tumor growth in vivo in an orthotopic xenograft model. Expression of 
MYC is required for E2-dependent proliferation, and MYC mRNA levels are induced 
by SRC by stabilization of MYC mRNA rather than activation of transcription. This 
stabilization required the RNA-binding protein DN-IMP1 which we found to be 
expressed in several ER-positive breast cancer cell lines. DN-IMP1 stabilization of 
MYC mRNA required SRC phosphorylation of Y260. 
We also observed a role for SRC in overcoming a p53 block to cell cycle 
progression after E2 stimulation. Loss of p53 in MCF7 cells abrogated a need for 
SRC in promoting cell cycle progression and proliferation in vitro. In an in vivo MCF7 
orthotopic xenograft model, we found that saracatinib inhibited growth of tumors 
regardless of p53 expression. Using shRNA-mediated knockdown of SRC, we also 
demonstrated that SRC was required for tumor grafting in mice. We also used an 
inducible shRNA system to knockdown SRC in established tumors. Here, we show 
SRC inhibition combined with loss of p53 led to static tumors whereas SRC inhibition 
in the presence of p53 leads to tumor regression. Loss of p53 led to an increase in 
MYC mRNA due to increased basal mRNA stabilization and an increase in DN-IMP1 
protein levels. Loss of p53 also abrogated the ability of E2 to stimulate MYC mRNA 
stabilization. Lastly, a defect in proliferation was observed in MCF7 cells 
overexpressing mutations of known SRC target tyrosines in MDM2 (Y281F/Y302F) 
suggesting a possibility for MDM2 as mediator of SRC inhibition of p53 function.
  1 
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Chapter I:  
Introduction:  
Important Effectors for Estrogen Receptor-Positive  
Breast Cancer Cell Proliferation 
 
  
  
3 
Introduction and Summary 
 
Estrogen Signaling and its Role in Estrogen Receptor-positive Breast 
Cancer  
 
Breast cancer is the most common cancer in women in the United 
States between 2009-2013 with an age-standardized incidence rate of 125.5 
per 100,000 (Jemal et al., 2017). Breast cancer can be classified into several 
clinical sub-types dependent upon the expression of three cellular receptors 
including the estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal receptor type 2 (HER2); or lack of expression of these receptors, 
classified as triple-negative breast cancer. The most common sub-type, 
estrogen receptor (ER)-positive breast cancer, accounts for the majority of 
breast cancer cases, between 60-80% of all diagnosed cases of breast cancer 
(Ali and Coombes, 2000; Miyoshi et al., 2010). This sub-type is characterized 
clinically by increased protein expression of the ER in tumor cells. Although 
increased expression of ER is used as a clinical marker, the mechanism by 
which the ER is upregulated is poorly understood. Several mechanisms 
including increased activation of the promoter of the gene, stabilization of the 
protein, and amplification of the gene have been studied (Ali and Coombes, 
2000; Carroll, 2016; Miyoshi et al., 2010). Despite lack of a complete 
understanding of this mechanism, therapeutics designed to disrupt the activity 
  
4 
of the ER have been effective in the clinic at treating ER-positive breast 
cancer. 
The ER is a nuclear hormone receptor that is activated upon binding of 
its natural ligand, 17-b-estradiol (estrogen, E2), and this activation has been 
shown to regulate the expression of target genes and promote the growth of 
ER-positive tumors (Marino et al., 2006). E2 acts as an agonist of the ER and 
upon binding, the ER is internalized by the cell, forms a homodimer, and 
translocates to the nucleus (DeMayo et al., 2002). In the nucleus, the ER 
homodimer binds to genomic DNA at estrogen responsive elements (EREs) 
and regulates its transcriptional gene targets. The ER can also form 
heterocomplexes with other transcription factors and be required for activation 
of transcription targets at other genomic sites. The transcriptional regulation of 
gene targets has been termed the E2 canonical, or genomic, signaling 
pathway (DeMayo et al., 2002; Fox et al., 2009; Marino et al., 2006; Sanchez 
et al., 2002). 
In addition to the canonical pathway, the ER has been described to be 
involved in rapid action, or non-genomic, signaling pathways (Ali and 
Coombes, 2000; Fox et al., 2009; Marino et al., 2006; Sanchez et al., 2002; 
Song et al., 2005; Vrtacnik et al., 2014). E2 stimulation and activation of the 
ER are required, however, signaling occurs in the cytoplasm rather than the 
nucleus. Several signaling pathways have been implicated in non-genomic E2 
signaling including SRC, MAPK, GPCRs, PKC, and PI3K (Castoria et al., 
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2001; Lobenhofer et al., 2000). The ER has been described to activate the 
MAPK pathway dependent upon an interaction between the ER and SRC 
(Migliaccio et al., 1996), and both the SRC and MAPK pathways may be 
required for E2-dependent proliferation (Castoria et al., 1999; Lobenhofer et 
al., 2000).  
In addition to downstream signaling, post-translational modifications of 
the ER have also been suggested to be important for E2-dependent 
proliferation. The ER contains a tyrosine residue (Y537) known to be 
phosphorylated by SRC and to be required for subcellular localization of the 
receptor as well as E2-dependent cell cycle proliferation (Arnold et al., 1995; 
Castoria et al., 2012). Additionally, a study using a six amino acid 
phosphorylated peptide mimic of the ER which competes in a dominant 
negative manner with the endogenous receptor for SRC binding was 
demonstrated to block cell proliferation as well as MCF7 tumor xenografts 
(Varricchio et al., 2007). This peptide also did not affect the transcriptional 
activity of the endogenous receptor providing more evidence that non-genomic 
signaling is important for cell cycle progression and tumor growth. These 
studies taken together suggest that the both the genomic and non-genomic E2 
signaling pathway are important for E2-dependent signaling, and more 
research would aid in understanding whether one or both of these pathways 
are primarily important for proliferation.  
  
6 
SRC in ER-positive Breast Cancer 
 
The protein tyrosine kinase SRC has been demonstrated to be involved 
in the initiation, progression, maintenance, and metastasis of breast cancer 
(Andrechek and Muller, 2000; Biscardi et al., 2000; Irby and Yeatman, 2000). 
In several studies, more than 70 percent of breast cancer patient samples 
have been demonstrated to have increased SRC expression as compared to 
normal breast epithelium as analyzed by either biochemical and 
immunohistochemical methods (Elsberger, 2014; Ottenhoff-Kalff et al., 1992; 
Verbeek et al., 1996). Additionally, one study found that increased expression 
of cytoplasmic SRC in ER-positive breast cancer samples relative to normal 
tissues correlated with reduced survival (Morgan et al., 2009). Another study 
found that active phosphorylated pY419SRC was increased in recurrent ER-
positive breast cancer (Planas-Silva et al., 2006). Taken together, these data 
suggest clinical relevance for SRC expression in ER-positive breast cancer. 
As described above, human ER-positive breast cancer has increased 
expression of SRC suggesting that SRC could have an important role in this 
breast cancer sub-type. Indeed, several mouse studies have found important 
roles for SRC during mammary gland development, E2 signaling, and 
tumorigenesis. SRC knockout mice have defects in mammary gland 
development, and E2 signaling was defective in mammary epithelial cells 
isolated from these mice (Kim et al., 2005). In a mouse model of breast cancer 
that was generated by expressing a mouse mammary tumor virus 
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(MMTV)/polyoma middle T antigen (PyVmT) fusion gene that generates rapid 
tumor development and metastases (Guy et al., 1992), SRC was shown to be 
required for tumorigenesis when the MMTV/PyVmT mice were crossed with 
src-/- mice and few, if any, tumors developed (Guy et al., 1994). The same 
requirement was not found to be true of the SRC family kinase (SFK), YES. 
When yes-/- mice were crossed with the MMTV/PyVmT mouse, tumors 
developed at nearly the same rate as in the wild-type mouse. Another mouse 
model in which SRC was conditionally knocked out in mammary epithelial cells 
to circumvent issues with impaired mammary gland development in the 
knockout mouse showed a similar defect in tumorigenesis in the PyVmT 
mouse as well as in cell cycle progression (Marcotte et al., 2012).  
These in vivo mouse models suggest an important role for SRC in the 
development and progression of breast cancer. The expression studies 
correlating increased SRC expression in most breast cancer, but also 
specifically ER-positive breast cancer also complements the findings from the 
mouse studies. These findings are consistent with the in vitro studies 
described above suggesting a role for SRC as a mediator of E2-dependent 
proliferation. Next, potential downstream effectors of ER- and SRC-mediated 
proliferation are discussed. 
Function and Regulation of p53  
 
In many cancer types, p53 is mutated and associated with both loss- 
and gain-of-functions that support tumor initiation, progression, and metastasis 
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(Aylon and Oren, 2007; Bargonetti and Manfredi, 2002; Goldstein et al., 2011; 
Woods and Vousden, 2001). Differing from most tumor types, ER-positive 
breast cancers typically express wild-type p53 (Caleffi et al., 1994; Dumay et 
al., 2013). It has been suggested that cancer cells which retain wild-type p53 
suppress its activity via other mechanisms. 
  The tumor suppressor, p53, has been described to have critical roles in 
regulating cell cycle arrest and apoptosis due to environmental stress and 
DNA damage (Aylon and Oren, 2007; Bargonetti and Manfredi, 2002; 
Goldstein et al., 2011; Woods and Vousden, 2001). Full activation of p53 
results in irreversible cell death, and its function is, therefore, tightly regulated. 
Regulation of p53 has been widely studied, including the stability of the p53 
protein, post-translational modifications to the protein (such as 
phosphorylation, acetylation, and ubiquitination), and interactions with other 
cofactors or regulators, including the p53 inhibitors, MDM2 and MDMX (Kruse 
and Gu, 2009). The classical model for p53 regulation focuses on stabilization 
of the protein after cellular stresses, including DNA damage, and binding to 
DNA to activate transcriptional regulation of target genes (Kruse and Gu, 
2009). However, more recent studies have suggested that p53 is much more 
complex. Basal levels of p53 are regulated by the E3 ubiquitin ligase, MDM2, 
which can inhibit p53 by ubiquitination to cause subcellular relocalization, 
proteasomal degradation of p53 (Haupt et al., 1997; Honda et al., 1997; 
Kubbutat et al., 1997) and by neddylation to inhibit transcriptional activity of 
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p53 (Xirodimas et al., 2004). Upon stress signaling, p53 can be stabilized, 
phosphorylated by Chk1, Chk2, ATM, and ATR (Appella and Anderson, 2001; 
Shieh et al., 2000; Shieh et al., 1997), or acetylated (Tang et al., 2008), and 
bound to its DNA target promoters. Additional post-translational modifications, 
including methylation by Set7/9 (Chuikov et al., 2004), neddylation by MDM2 
(Xirodimas et al., 2004), and sumoylation (Carter et al., 2007; Melchior and 
Hengst, 2002) of p53, then allow for formation of distinct transcriptional 
complexes to form and allow for fine-tuned functional responses including 
senescence, cell cycle arrest, DNA repair, apoptosis, or autophagy (Kruse and 
Gu, 2009). Clearly, p53 activation is a very complex process being regulated 
at multiple levels to ensure proper maintenance of the cell. Specific cellular 
functions are likely governed via cooperation between multiple signaling 
pathways, and sequential modifications of p53 are likely required for proper 
responses to cellular stresses, and this field of study remains an area of active 
research. 
 Although p53 regulation is very complex, the roles of MDM2 and MDMX 
have been more well studied and have provided hints about their roles in p53 
regulation. Although MDM2 and MDMX are structurally similar, they play 
different, non-overlapping roles in p53 inhibition (Marine et al., 2006). Both 
MDM2 (Jones et al., 1995; Montes de Oca Luna et al., 1995) and MDMX 
(Migliorini et al., 2002; Parant et al., 2001) knockout mice are embryonic lethal, 
however, inactivation of p53 in either background completely rescues the 
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lethal phenotype suggesting that these two proteins individually are critical 
inhibitors of p53. Unlike MDM2 which has E2 ligase activity towards p53, 
MDMX does not have ligase activity, but has been described to affect p53 
transcriptional activity (Marine and Jochemsen, 2005). MDM2 and MDMX 
individually interact with p53 but also interact with each other, and the 
MDM2/MDMX complex has been shown to lead to more efficient ligase activity 
of MDM2 (Linares et al., 2003). An additional mouse study wherein the MDM2 
interaction site on MDMX was mutated in the presence of endogenous MDM2, 
also resulted in embryonic lethality able to be rescued by p53 inactivation 
suggesting that the interaction between the two is also critical for p53 
regulation (Huang et al., 2011).  
 The interaction of MDM2 and MDMX has been shown to be dependent 
upon MDM2 phosphorylation by the tyrosine kinase ABL ultimately leading to 
p53 inactivation (Waning et al., 2011). A knock-in mouse model was 
generated by mutating the ABL phosphorylation site on MDM2 Y393F, and 
these mice spontaneously developed tumors, however, stabilization of p53 
protein was unaffected (Carr et al., 2016). Although these studies suggest a 
role for ABL in inhibiting p53 function, conflicting reports also suggest a role for 
ABL in activating p53. ABL can interfere with MDM2 interaction with p53 
(Sionov et al., 2001; Sionov et al., 1999), and also phosphorylate MDMX 
inhibiting its interaction with p53 (Zuckerman et al., 2009).  
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Many of the studies described above have primarily focused on 
regulation of p53 in the context of the DNA damage or apoptotic response. 
ABL regulation of MDM2 and MDMX is of particular interest for this work, 
because while ABL has been implicated in DNA damage and apoptosis, ABL 
also has been implicated in control of the cell cycle which will be discussed in 
more depth below. 
Role of p53 Cell Cycle Regulation in Growth Factor and Estrogen 
Signaling 
 
Many functions of p53 have been elucidated using DNA damage as a 
stimulus, which results in stabilization of p53 protein and often a full apoptotic 
response (Bargonetti and Manfredi, 2002; Kruse and Gu, 2009; Woods and 
Vousden, 2001). Apoptosis is irreversible; however, cell cycle arrest is not 
suggesting that cell cycle arrest is potentially an acute function of p53 distinct 
from apoptosis. Less work has been focused on understanding the role of p53 
in suppression of cell cycle progression. Increases in p53 expression have 
been observed in quiescent cells, suggesting that p53 could be causing a 
G0/G1 cell cycle block (Itahana et al., 2002). Correlating with this, some 
studies have implicated inhibition of p53 and increased expression of MDM2 in 
growth factor-stimulated release from quiescence (Lei et al., 2011; Leri et al., 
1999; Quintavalle et al., 2010; Ries et al., 2000; Shaulian et al., 1997). These 
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data suggest that signaling via MDM2 may play a role in regulating a p53 cell 
cycle block. 
Our lab has previously shown that quiescent cells stimulated with 
peptide growth factors require SRC to progress into the cell cycle (Roche et 
al., 1995; Twamley-Stein et al., 1993). However, cells lacking p53 no longer 
require SRC activity to enter the cell cycle upon growth factor stimulation 
(Broome and Courtneidge, 2000; Furstoss et al., 2002; Klinghoffer et al., 
1999). SRC has also been shown to activate ABL, which is also required for 
proliferation only in cells expressing functional p53 (Furstoss et al., 2002). ABL 
is also a downstream effector required for transformation by active SRC 
(Sirvent et al., 2007). 
Experiments in several other systems are also consistent with a role for 
SRC inhibition of p53. The polyoma virus large T or middle T antigens do not 
inhibit p53 nor promote degradation of p53 unlike other tumor viruses 
(Dilworth, 1990) which target p53 directly. However, transformation by 
polyoma middle T requires the association and activation of SRC 
(Courtneidge, 1985; Courtneidge and Smith, 1983) and these data taken 
together potentially suggest that SRC may indirectly mediate p53 inhibition. 
Activated SRC has also been shown to reduce expression of p53 in vascular 
smooth muscle cells and NIH3T3 cells to promote podosome formation 
(Mukhopadhyay et al., 2009). In another study using vascular smooth muscle 
cells, our lab showed that SRC inhibited p53-regulated miRs that regulated 
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podosome formation (Quintavalle et al., 2010). In a model of proliferative 
vitreoretinopathy, activated PDGFRa has been shown to suppress expression 
of p53 further implicating p53 as a downstream target of growth factor 
signaling (Lei et al., 2011). 
In addition to growth factor inhibition of p53, several studies have also 
shown that E2 signaling may inhibit p53 function indirectly (Bailey et al., 2012; 
Berger et al., 2012; Konduri et al., 2010; Rieber and Strasberg-Rieber, 2014). 
A direct interaction of the ER with p53 has also been described to modulate its 
transcriptional activity (Liu et al., 2006; Menendez et al., 2010). Given the data 
that individually, the ER and SRC have been implicated in the inhibition of p53, 
it remains to be fully tested whether SRC mediates p53 inhibition downstream 
of E2 signaling. However, several clinical studies have provided hints into SRC 
playing a role in ER-positive breast cancer. Preclinical and clinical trials using 
multi-targeted kinase inhibitors that inhibit SRC, including dasatinib (Mayer et 
al., 2011; Mitri et al., 2016) and bosutinib (Campone et al., 2012; Hebbard et 
al., 2011) have been largely disappointing, but there were some hints of 
response in hormone receptor (HR)-positive breast  cancer. These trials did 
not take into account p53 status of the HR-positive patients, but as we 
described earlier, most ER-positive breast cancer patients express wild-type 
p53. Additionally, loss of p53 function typically occurs during cancer 
progression, and many of the patients in these trials are in the late stages of 
progression which likely correlates with p53 loss. Thus, while SRC inhibition in 
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the clinic has had some limited efficacy resulting in stable disease in HR-
positive breast cancer, the trials may in general been targeting the appropriate 
population. The data suggesting that SRC inhibits p53 function taken with the 
clinical trial data suggests that additional research should be conducted to test 
whether p53 may be an important biomarker for SRC inhibition. 
Function and Regulation of MYC  
 
MYC is a transcription factor known to promote proliferation and has 
also been described to be important in breast cancer (Liao and Dickson, 
2000). MYC expression is typically high in breast cancer, however, this does 
not appear to be due to amplification of the gene (Deming et al., 2000). 
Transgenic mouse models have also shown that MYC expression on its own is 
enough to induce tumors in breast tissues (Liao and Dickson, 2000; Meyer 
and Penn, 2008). Because of this potent tumorigenic function of MYC, the 
gene and its protein product are tightly regulated. 
MYC is regulated by several means including at the transcriptional 
(Dubik and Shiu, 1988; Ho et al., 2005; Santos et al., 1988; Zou et al., 1997), 
post-transcriptional (Blanchard et al., 1985; Dean et al., 1986; Kindy and 
Sonenshein, 1986; Nepveu et al., 1987), and post-translational (Sears et al., 
1999; Sears et al., 2000) levels. Phosphorylation of MYC is known to stabilize 
its protein levels and direct its activity (Sears et al., 1999; Sears et al., 2000). 
Post-transcriptionally, MYC mRNA is known to be regulated by cis-elements 
within its mRNA sequence including a coding region determinant (CRD) 
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(Ioannidis, 2005; Ioannidis et al., 2005; Lemm and Ross, 2002; Noubissi et al., 
2006; Sparanese and Lee, 2007; Weidensdorfer et al., 2009), and AU 
elements and miRNA regulation sites within the MYC 3’-UTR (Guhaniyogi and 
Brewer, 2001; Ross, 1995; Sachdeva et al., 2009). Several RNA-binding 
proteins have been shown to regulate the half-life of MYC mRNA via these cis-
elements including stabilization by insulin growth factor 2 binding protein 1 
(IMP1, IGF2BP1, CRD-BP, ZBP1) (Barnes et al., 2015; Ioannidis et al., 2005; 
Weidensdorfer et al., 2009) or destabilization by tristetraprolin (TTP) 
(Marderosian et al., 2006; Rounbehler et al., 2012). Interestingly, IMP1 is 
typically expressed during development, but has been demonstrated to be re-
expressed in several tumor types and cell lines (Bell et al., 2013; Ioannidis et 
al., 2004; Ioannidis et al., 2003; Ioannidis et al., 2005; Köbel et al., 2007) 
including breast cancer. A recent report also suggests that a truncated form of 
the protein, DN-IMP1 is expressed in the MCF7 cell line, an ER-positive breast 
cancer cell line (Fakhraldeen et al., 2015). With many levels of regulation, 
mechanisms that may regulate MYC dependent upon ER signaling are 
discussed next.  
MYC as an Effector of ER- and SRC-Regulated Proliferation 
 
MYC has been shown to be a downstream effector for both the ER and 
SRC. MYC has also been described to be required for E2-dependent breast 
cancer cell proliferation (Shiu et al., 1993). An additional study showed that 
inducible MYC expressed in MCF7 cells could overcome cell cycle block due 
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to ICI182870 (Prall et al., 1998). Several studies have suggested that MYC is 
regulated transcriptionally by E2 stimulation (Dubik et al., 1987; Dubik and 
Shiu, 1988; Shiu et al., 1993; Wang et al., 2011), however, there has not been 
a canonical ERE discovered in the MYC promoter (Dubik and Shiu, 1992). 
Other studies have suggested that MYC is regulated post-transcriptionally by 
E2 (Santos et al., 1988). 
In line with the possibility that MYC may be regulated post-
transcriptionally by E2 non-genomic signaling, growth factor signaling studies 
have also suggested that MYC is regulated by this mechanism (Blanchard et 
al., 1985; Bromann et al., 2005; Dean et al., 1986; Greenberg and Ziff, 1984; 
Kelly and Siebenlist, 1986; Kindy and Sonenshein, 1986; Nepveu et al., 1987). 
Downstream of growth factor signaling, our lab has demonstrated a role for 
SRC in mediating MYC mRNA stability in response to PDGF stimulation 
(Bromann et al., 2005). Our studies have also demonstrated that MYC 
expression can overcome a cell cycle block due to SFK inhibition by dominant 
negative SFKs (Barone and Courtneidge, 1995) and also that MYC mRNA 
was regulated by SFK activity confirmed by use of an SFK inhibitor (Blake et 
al., 2000).  
Concluding Remarks 
 
E2 signaling in has been extensively studied, in particular, the genomic 
signaling pathway, but many open research questions remain regarding the 
non-genomic signaling pathway and its contribution to ER-positive breast 
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cancer growth and progression. Much research has focused on the roles and 
regulation of the ER, SRC, p53, and MYC, however, the tight and complex 
regulation of each remains to be fully understood. The underlying biology of 
these signaling pathways may serve to better inform selection of patient 
biomarkers (perhaps p53 status and ER-status) as well as therapeutic 
selection (SRC inhibition). 
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Chapter II: 
SRC is Required for Estrogen-dependent Proliferation in Estrogen 
Receptor-positive Breast Cancer Cells by Stabilizing MYC mRNA 
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Abstract 
 
  Estrogen (E2) stimulation promotes proliferation in estrogen receptor 
(ER)-positive breast cancer, which accounts for 60-80% of all breast cancer. 
The tyrosine kinase SRC is also expressed highly in ER-positive breast 
cancer. A non-genomic E2 signaling pathway involving SRC family kinases 
(SFKs) has been implicated in regulating the cell cycle downstream of the ER, 
however, little is known about this pathway. Using an in vitro ER-positive 
breast cancer cell model, MCF7 or ZR75-1, cells were stimulated with E2 and 
either pretreated with an SFK inhibitor (SU11333) or shRNA-mediated 
knockdown of SRC or YES. SFK inhibition blocked G1/S progression and 
proliferation. We tested the SRC/ABL inhibitor, saracatinib, in an orthotopic 
xenograft mouse model of ER-positive breast cancer and observed decreased 
tumor growth upon treatment. 
As MYC is a known target of both the ER and SRC and a known driver 
of cell cycle progression, we tested whether MYC could be mediating SRC’s 
proliferative effects in this model. Using MYC-targeting shRNA, we showed 
that MYC is required for E2-dependent cell cycle progression and proliferation. 
Additionally, E2 stimulates MYC mRNA expression dependent upon SRC. We 
also showed that MYC mRNA expression is mediated by SRC-dependent 
mRNA stabilization, but not transcription. We next aimed to understand the 
mechanism by which non-genomic ER-SRC signaling drives proliferation in 
ER-positive breast cancer cells. A known stabilizer of MYC mRNA, the RNA-
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binding protein IMP1, has a truncated form (ΔN-IMP1) which we show to be 
expressed in ER-positive breast cancer cell lines. Our data suggests that ΔN-
IMP1 is required for the SRC-mediated stabilization of MYC mRNA and 
proliferation. Taken together, these data suggest that SRC mediates cell cycle 
progression and proliferation through a non-genomic E2 signaling pathway by 
stabilizing MYC mRNA.  
  
  
33 
Introduction 
 
The protein tyrosine kinase, SRC, has been studied as a mediator of 
estrogen (E2)-dependent proliferation for some time (Andrechek and Muller, 
2000; González et al., 2006; Shupnik, 2004). In normal and cancerous breast 
epithelial cells, SRC has been shown to be required for E2-dependent 
proliferation in cells expressing the estrogen receptor (ER) (Arnold et al., 1995; 
Guy et al., 1992; Guy et al., 1994; Kim et al., 2005; Marcotte et al., 2012). E2 
binding to the ER activates SRC as well as MAPK (Migliaccio et al., 1996; 
Migliaccio et al., 1998). Several studies have also suggested that SRC 
phosphorylates the ER at tyrosine 537 and that this phosphorylation is 
important for their interaction as well as proliferation (Arnold et al., 1995; 
Castoria et al., 2012; Song et al., 2005; Yudt et al., 1999).  
SRC has largely been suggested to have a role in the non-genomic 
estrogen signaling pathway regulating proliferation (DeMayo et al., 2002; Fox 
et al., 2009; Hammes and Levin, 2007; Marino et al., 2006; Shupnik, 2004; 
Song et al., 2005). There is evidence that the non-genomic pathway is 
important for E2-dependent proliferation. Two studies in which ER mutants 
lacking the ability to bind DNA were exogenously expressed in cells lacking 
endogenous ER expression were shown to enter S phase upon E2 stimulation 
(DeNardo et al., 2007). Interestingly, if these cells also expressed a kinase-
dead version of SRC, interfering with kinase activity by acting as a dominant-
negative, both the wild-type and mutant ER-expressing cells were able to 
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progress through the cell cycle (Castoria et al., 1999; DeNardo et al., 2007). In 
addition to SRC data also suggests that the PI3K and MAPK signaling 
pathways are also required for E2-dependent S phase entry (Castoria et al., 
2001; Migliaccio et al., 1996; Migliaccio et al., 1998). This hints that 
cytoplasmic signaling pathways may be important for regulating proliferation in 
a non-genomic signaling pathway. These data suggest that SRC-mediated E2-
dependent proliferation is likely independent of the estrogen receptor’s 
transcriptional activity. Supporting this claim, no canonical estrogen 
responsive element (ERE) has been found in the MYC promoter (Dubik and 
Shiu, 1992). 
 Both the ER (Dubik et al., 1987; Dubik and Shiu, 1988; Dubik and Shiu, 
1992; Santos et al., 1988; Shiu et al., 1993; Wang et al., 2011) and SRC 
(Barone and Courtneidge, 1995; Blake et al., 2000; Bowman et al., 2001; 
Furstoss et al., 2002; Prathapam et al., 2006) have been demonstrated to 
regulate expression of the transcription factor, MYC, as a requirement for S 
phase entry. In the studies using the ER DNA-binding mutants, it was shown 
that E2 stimulation was still able to induce MYC mRNA expression (DeNardo 
et al., 2007). Inducing expression of MYC in MCF7 cells pretreated with 
fulvestrant, an anti-estrogen (ICI182780) is able to overcome a G1 cell cycle 
block (Prall et al., 1998).  
MYC has been described to be important in breast cancer progression 
(Liao and Dickson, 2000). MYC expression is typically high in breast cancer, 
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however, this does not appear to be due to amplification of the gene (Deming 
et al., 2000). MYC has also been shown to be required for E2-dependent 
breast cancer cell proliferation (Shiu et al., 1993). MYC is highly regulated at 
the transcriptional (Dubik and Shiu, 1988; Santos et al., 1988; Zou et al., 
1997), post-transcriptional (Blanchard et al., 1985; Dean et al., 1986; Kindy 
and Sonenshein, 1986; Nepveu et al., 1987), and post-translational (Sears et 
al., 1999; Sears et al., 2000) levels. Phosphorylation of MYC is known to 
stabilize its protein levels and direct its activity (Sears et al., 1999; Sears et al., 
2000). Also, MYC mRNA half-life is known to be regulated by cis-elements 
within its mRNA sequence including a coding region determinant (CRD) 
(Ioannidis, 2005; Ioannidis et al., 2005; Lemm and Ross, 2002; Noubissi et al., 
2006; Sparanese and Lee, 2007; Weidensdorfer et al., 2009), and AU 
elements and miRNA regulation sites within the MYC 3’-UTR (Guhaniyogi and 
Brewer, 2001; Ross, 1995). Several RNA-binding proteins have been shown 
to regulate the half-life of MYC mRNA via these cis-elements including 
stabilization by insulin growth factor 2 binding protein 1 (IMP1, IGF2BP1, 
CRD-BP, ZBP1) (Barnes et al., 2015; Ioannidis et al., 2005; Weidensdorfer et 
al., 2009) or destabilization by tristetraprolin (TTP) (Marderosian et al., 2006; 
Rounbehler et al., 2012). Interestingly, IMP1 is typically expressed during 
development, but has been demonstrated to be re-expressed during cancer 
progression in several tumor types and cell lines (Bell et al., 2013; Ioannidis et 
al., 2004; Ioannidis et al., 2003; Ioannidis et al., 2005; Köbel et al., 2007) 
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including breast cancer. There is also a recent report suggesting that a 
truncated form of the protein, ∆N-IMP1 is re-expressed in the MCF7 ER-
positive breast cancer cell line and is sufficient to rescue clonal outgrowth in 
cells lacking both forms of IMP1 (Fakhraldeen et al., 2015).  
 Although the rapid, non-genomic E2 signaling pathway is often cited as 
part of the ER pathway, relatively little is known about it outside of the likely 
signaling kinases involved including MAPK, PI3K, and SRC (Castoria et al., 
1999; Lobenhofer et al., 2000). Here, we characterize the role of SRC in E2-
dependent proliferation in the context of ER-positive breast cancer cells.  
 
Results 
SRC is Required for E2-dependent Proliferation in vitro and in vivo. 
Using the ER-positive breast cancer cell line, MCF7 (Figure 2.1), we 
aimed to test whether SRC family kinases (SFKs) were required for E2-
dependent proliferation. Using a small molecule inhibitor of SFK activity, 
(SU11333), we serum-starved MCF7 cells for 48 hours to quiesce the cells 
prior to stimulation with E2. Upon stimulation of cells with E2, we observed an 
increase in levels of pY418-SRC that was abolished after pre-treatment with 
SU11333 (Figure 2.1). We then aimed to test whether SFK activity was 
required for cell cycle progression and proliferation. Using BrdU incorporation 
as a surrogate for G1/S transition, we E2-stimulated cells that had been 
pretreated with either ICI182870, an anti-estrogen, or SU11333. E2 stimulated 
entry into S phase as seen by an increase in BrdU incorporation (Figure 2.1).  
  
37 
 
Figure 2.1: SRC, but not YES, is required for E2 stimulated proliferation. 
(A) Representative immune blot of quiescent MCF7 cells pretreated with 
vehicle or 1 µM SU11333 and stimulated with vehicle or 5nM E2. (B) BrdU 
incorporation assay or (C) proliferation assay of quiescent MCF7 cells 
pretreated with 10 nM ICI182870 or 1 µM SU11333 and treated with vehicle or 
5 nM E2 and BrdU. (D) Representative immunoblot analysis of either shCtrl or 
shSRC stable knockdown MCF7 lines. BrdU incorporation assay or (E) 
proliferation assay of quiescent shCtrl or shSRC stable knockdown MCF7 
lines. (F) Orthotopic MCF7 xenografts in female nude mice. Mice were injected 
with MCF7 cells at Day 0. Intraperitoneal treatment with DMSO, ICI182870, or 
saracatinib was performed every three days and tumors measured at the 
same time. (G) Representative immunoblot analysis of either shCtrl or shYES 
stable knockdown MCF7 lines. BrdU incorporation assay or (H) proliferation 
assay of quiescent shCtrl or shYES stable knockdown MCF7 lines. *=p<0.05, 
**=p<0.01. 
 
 
Both ICI182870 and SU11333 blocked E2-dependent BrdU incorporation 
suggesting that both the E2 stimulus and SFK activity were required to 
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transition to S phase. To test whether this was an acute cell cycle delay or a 
sustained cell cycle block, we also performed a proliferation assay. The 
ICI182870 and SU11333 inhibitor treated cells were unable to proliferate as 
compared to E2 stimulated cells (Figure 2.1) providing evidence of a long-term 
persistent block to proliferation.  
 Because SU11333 inhibits several SFKs (Guan et al., 2004), we 
wanted to determine whether the cell cycle block was due specifically to SRC 
or one of the other SFKs. MCF7 cells express SRC at high levels, but also the 
SFK family member, YES, at low to moderate levels (Figure 2.1). We therefore 
aimed to test the requirement for these SFKs in cell cycle progression and 
proliferation independently using shRNA-mediated knockdown (Figure 2.1). In 
shSRC cells, BrdU incorporation and proliferation were both inhibited relative 
to shCtrl cells. However, shYES cells showed no statistical difference in BrdU 
incorporation or proliferation from shCtrl cells (Figure 2.1). These data suggest 
that SRC is the main SFK required for cell cycle progression and proliferation 
due to E2 stimulation, and that the kinase activity is required for these 
functions. 
  To further test the role of SRC in ER-positive breast cancer 
proliferation and growth, we next aimed to test whether SRC was required for 
in vivo tumor growth in an orthotopic xenograft model in immunocompromised 
mice. MCF7 cells have been demonstrated to require sustained E2 stimulation 
via an implanted E2 pellet to grow as tumors in mice. Using female nude mice, 
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we first injected the slow-release E2 pellets into the mice one week prior to 
injection of cells. For cell injection, 1x 106 cells were resuspended in PBS and 
mixed with Matrigel at 1:1 and a final volume of 100 µl was injected into the 
fourth mammary gland of the mouse. To test the requirement of SRC kinase 
activity in the mice, we used the clinically available SRC+ inhibitor, saracatinib, 
although we acknowledge that this inhibitor has additional kinase targets 
(Green et al., 2009). At a volume of 50 mm3, we randomized the mice into 
treatment groups consisting of DMSO vehicle control, 10 mg/Kg ICI182870, 
and 25 mg/Kg or 50mg/Kg saracatinib (Figure 2.1). Mice were injection 
intraperitoneally every three days and tumors were measured at the same 
time. The vehicle treated tumors grew to an average of 400 mm3 by day 45 
(Figure 2.1). As a control for the MCF7 cells requiring E2 for growth in vivo, 
inhibition of the E2 stimulation with ICI182870 caused regression of all treated 
tumors (Figure 2.1). Treatment of the tumors with the lower dose of saracatinib 
caused a significant decrease in tumor growth of MCF7 cells. At the higher 
dose, tumors regressed similar to those treated with the anti-estrogen (Figure 
2.1). Overall, our in vivo data is consistent with the in vitro data that SRC 
activity is required in MCF7 cells for E2-dependent cellular proliferation and 
tumor growth. To demonstrate that this was not a cell line specific effect, we 
also performed similar in vitro assays using another ER-positive breast cancer 
cell line, ZR-75-1, and observed similar effects in BrdU incorporation and 
proliferation assays using SU11333 (Figure 2.2).  
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Figure 2.2: ZR-75-1 cells require SFKs for E2-dependent proliferation, 
MYC mRNA accumulation, and MYC mRNA stabilization. (A) BrdU 
incorporation assay or (B) proliferation assay of quiescent ZR-75-1 cells 
pretreated with 10 nM ICI182870 or 1 µM SU11333 and treated with vehicle or 
5 nM E2 and BrdU. **=p<0.01, ***=p<0.001 
 
Estrogen Stimulates SRC-dependent Expression of MYC. 
Previous studies had suggested that MYC expression is required for 
E2-dependent proliferation. We wanted to test whether MYC was required for 
E2-dependent cell cycle progression in the MCF7 cells using shRNA-mediated 
knockdown of MYC mRNA. After achieving an efficient knockdown of MYC in 
the stable cells as analyzed by immunoblot (Figure 2.3), we used these cells 
and performed BrdU incorporation and proliferation assays. E2 was unable to 
stimulate the shMYC cells to enter S-phase compared to the control cells 
(Figure 2.3). As we had implicated a SFK activity for BrdU incorporation, we 
also wanted to teste whether SFK activity was required for cell cycle 
progression in shMYC cells. While SU11333 was able to block BrdU 
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incorporation in shCtrl cells relative to E2-stimulated cells, we did not observe 
a difference between the E2 stimulated and SU11333-treated shMYC cells 
(Figure 2.3). This suggested a potential role for SFKs upstream of MYC during 
G1/S transition. Down-regulation of MYC also led to a decrease in proliferation 
over several days (Figure 2.3).  
 As both the ER and SRC have been implicated in regulating expression 
of MYC mRNA, we wanted to test whether E2 was able to stimulate MYC 
mRNA expression and if so was SRC required. Indeed, E2 was able to 
stimulate MYC mRNA levels in a concentration dependent manner as well as 
over time after stimulation with 5 nM E2 relative to the cells treated with 
vehicle (Figure 2.4). To test whether SRC was required for this increase, we 
again used either SU11333 or shSRC knockdown cells. MYC mRNA levels 
 
 
 
Figure 2.3- MYC is required for E2-dependent proliferation. (A) 
Representative immunoblot of shCtrl of shMYC MCF7 cells. BrdU 
incorporation assay of quiescent shCtrl or shMYC stable knockdown MCF7 
lines pretreated with 1 µM SU11333 and treated with vehicle or 5 nM E2 and 
BrdU (B) proliferation assay of quiescent shCtrl or shMYC stable knockdown 
MCF7 lines treated with vehicle or 5 nM E2. *=p<0.05, **=p<0.01. 
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were not induced upon any concentration of E2 stimulation or at any time after 
E2 stimulation in either the inhibitor-treated or the shSRC cells (Figure 2.4). 
We also observed that SU11333 could block MYC mRNA accumulation in ZR-
75-1 cells (Figure 2.4). These data suggest that SRC activity is required for 
MYC mRNA accumulation after E2 stimulation. 
SRC Mediates E2-dependent Expression of MYC mRNA by Stabilizing Its 
mRNA Levels. 
We next aimed to investigate the possible mechanism of MYC mRNA 
accumulation after E2-stimulation. As E2 has previously been reported to 
transcriptionally activate MYC mRNA (Dubik and Shiu, 1988), we first 
performed a nuclear run-on assay to test whether MYC mRNA transcription 
was induced in our system (Figure 2.5). We stimulated quiescent cells with E2 
and then paused transcription on ice at various time points. We isolated intact 
nuclei from each time point for analysis. We next added labeled 5-ethynyl 
Uridine (EU), and placed samples at 37C to allow for elongation of initiated 
transcripts and incorporation of the EU. The EU was then biotinylated and 
collected using streptavidin beads to collect only actively transcribed mRNAs. 
RNA was then isolated, cDNA was generated, and qPCR analysis was 
performed. The housekeeping gene, PPIA, was analyzed as a negative control 
as E2 should not stimulate its transcription (Figure 2.5). As a positive control, 
we measured the transcription of PS2, a known transcriptional target of the ER 
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(Brown et al., 1984; Kim et al., 2000), and observed an increase in PS2 
transcription after E2 stimulation (Figure 2.5). However, we did not detect an 
 
Figure 2.4- E2 induces MYC mRNA accumulation dependent on SRC. (A) 
Left: qPCR analysis of quiescent MCF7 cells that were pretreated with vehicle 
or 1 µM SU11333 and treated with increasing [E2] or Right: with 5 nM over 90 
min. (B) Left: qPCR analysis of quiescent shCtrl or shSRC MCF7 lines that 
were pretreated with vehicle or 1 µM SU11333 and treated with increasing 
[E2] or Right: with 5 nM over 90 min. (C) Left: qPCR analysis of quiescent ZR-
75-1 cells that were pretreated with vehicle or 1 µM SU11333 and treated with 
increasing [E2] or Right: with 5 nM over 90 min. *=p<0.05 
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increase in transcription of MYC mRNA after E2-stimulation (Figure 2.5). For 
each time point, we also had collected the cytoplasmic fractions of mRNA. 
Interestingly in the cytoplasm, we observed an increase in both PS2 mRNA as 
well as MYC mRNA, but not in PPIA mRNA (Figure 2.5). These data taken 
together suggest that in our system, MYC mRNA is not being regulated via 
transcription of the gene, but rather post-transcriptionally. 
 As we observed an increase in cytoplasmic levels of MYC mRNA, but 
not in transcription, we next aimed to test whether MYC mRNA was being 
regulated by another mechanism. There is evidence that E2 may be regulating 
MYC mRNA post-transcriptionally by stabilizing the transcript (Santos et al., 
1988). We tested this by stimulating cells for sixty minutes with 5 nM E2 to 
detect increases in MYC mRNA. We then treated the cells with Actinomycin D 
to block transcription and isolated RNA from the cells at various time points 
after Actinomycin D treatment. Compared to the basal decay of MYC mRNA 
as observed in vehicle treated cells, we detected an increase in stabilization of 
MYC mRNA in E2-stimulated cells (Figure 2.5). This stabilization was not 
observed with PS2 mRNA suggesting that upon E2-stimulation (Figure 2.5), 
these two genes are regulated by different mechanisms. We also observed 
similar results in the ZR-75-1 cells (Figure 2.5). 
We previously published that SRC regulated MYC by stabilizing its 
mRNA in fibroblasts after PDGF stimulation (Bromann et al., 2005) so we  
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Figure 2.5: E2 stimulation induces MYC mRNA stabilization, not MYC 
transcription. (A) Nuclear run-on assay of MCF7 cells treated with E2 over a 
time course. (B) Cytoplasmic fractions from the same samples as the nuclear 
run on assay in (A). MYC mRNA stability assay in (C) MCF7 cells or (D) shCtrl 
and shSRC MCF7 cells or (E) ZR-75-1 cells pretreated with vehicle or 1 µM 
SU11333 and stimulated with vehicle or 5nM E2. After 60 min, cells were 
treated with 5 µM Actinomycin D to block transcription. *=p<0.05 
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hypothesized that E2 was able to stabilize MYC mRNA also dependent upon 
SRC. To test this hypothesis, we again used either SU11333 or shSRC 
knockdown cells and performed the mRNA stability assay. E2-stimulated MYC 
mRNA stability was abrogated upon inhibition of SFKs by SU11333 or shSRC 
knockdown (Figure 2.5). Also, SRC inhibition had no effect on PS2 half-life. 
SFK inhibition also blocked the MYC mRNA stabilization after E2 stimulation in 
ZR-75-1 cells (Figure 2.5). 
ΔN-IMP1, a Truncated Form of the RNA-binding Protein, IMP1, is 
Required for MYC mRNA Stability   
To test the mechanism behind MYC mRNA stabilization, we first 
hypothesized that a candidate RNA-binding protein, IMP1, could be involved. 
IMP1, a developmentally expressed RNA-binding protein, has been shown to 
be re-expressed in cancer (Ioannidis, 2005; Kim et al., 2017; Köbel et al., 
2007). IMP1 has also been demonstrated to stabilize MYC mRNA in a variety 
of cell types (Bell et al., 2013; Fakhraldeen et al., 2015; Kim et al., 2017; 
Weidensdorfer et al., 2009). We first performed qPCR analysis to test whether 
IMP1 was expressed at the RNA level in our ER-positive breast cancer lines 
as well as 293T cells known to express IMP1 (Figure 2.6). We did not detect 
any expression at the RNA level of IMP1 in our cell lines, although we did in 
the 293T cells (Figure 2.6). However, a recent report suggested that there was  
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Figure 2.6- DN-IMP1 is expressed in ER-positive breast cancer cell lines. 
(A) RT-PCR analysis of RNA expression in 293T, MCF7 and ZR-75-1. (B) 
Representative immunoblot analysis of 293T, MCF7, and QR-75-1 cell lysates 
and probing for FL-IMP1 (CS) or FL-IMP1/DIMP1 (Sigma). (C) Validation of 
shRNA knockdown in 293T of FL-IMP1 (sh8079) or FL-IMP1/DIMP1 (sh5149). 
(D) Representative immunoblot analysis of ER-positive breast cancer cell lines 
for FL-IMP1/DIMP1 expression. 
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also truncated form of the protein, ΔN-IMP1, that was expressed in some 
cancer cell lines, including MCF7 (Fakhraldeen et al., 2015). We used primers 
specific for the truncated form, and indeed ΔN-IMP1 is expressed at the RNA 
level in both ER-positive cell lines that we tested, MCF7 and ZR-75-1, as well 
as at low levels in the 293T cells (Figure 2.6). We next analyzed protein 
lysates from 293T, MCF7, and ZR-75-1 by immunoblot and detecting IMP1 
expression using two antibodies. The CS antibody detects an epitope only 
present in FL-IMP1, but the Sigma antibody can detect both FL-IMP1 as well 
as ΔN-IMP1. Similar to the qPCR results, we found that the MCF7 and ZR-75-
1 cells expressed only the short form, while the 293T cells expressed primarily 
FL-IMP1, but also ΔN-IMP1 at low levels (Figure 2.4). We next wanted to 
analyze the expression of IMP1 and ΔN-IMP1 protein in several ER-positive 
breast cancer cell lines. We were able to detect ΔN-IMP1 in all of the cell lines 
that we tested while none expressed the full-length form (Figure 2.6). Because 
we detected multiple bands in some of the immunoblots, we generated stable 
knockdown in either 293T cells (Figure 2.6) or MCF7 cells (Figure 2.7) using 
shRNAs that targeting either FL-IMP1 only (sh8079) or both forms of IMP1 
(sh5149). Immunoblot analysis demonstrated that indeed the constructs we 
used were able to specifically knockdown the FL-IMP1 or both forms of IMP1. 
 We hypothesized that either FL-IMP1 or ΔN-IMP1 could be required for 
MYC mRNA stabilization so we used the MCF7 shCtrl of sh5149 knockdown 
cells and compared them to scrambled control (shCtrl) cells in the RNA  
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Figure 2.7: DN-IMP1 is required for MYC mRNA stabilization after E2 
stimulation. (A) Representative immunoblot of shCtrl, sh8079 (FL-IMP1), or 
sh5149(FL-IMP1/ DIMP1) knockdown in MCF7 cells. MYC mRNA stability 
assay shCtrl, sh8079, and sh5149 MCF7 cells pretreated with vehicle or 1 µM 
SU11333 and stimulated with vehicle or 5nM E2. After 60 min, cells were 
treated with 5 µM Actinomycin D to block transcription. (B) (left) 
Representative immunoblot of sh5149 knockdown MCF7 cells also expressing 
either empty vector or DIMP1. (right) MYC mRNA stability assay empty vector 
or DIMP1 expressing sh5149 knockdown MCF7 cells pretreated with vehicle or 
1 µM SU11333 and stimulated with vehicle or 5nM E2. *=p<0.05 
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stability assay and measured MYC mRNA half-life (Figure 2.7). The sh8079 
cells behaved similar to shCtrl cells in this assay (Figure 2.7). However, 
sh5149 cells that targeted both forms of IMP1 were unable to stabilize MYC 
mRNA upon E2 stimulation (Figure 2.7). This suggested that one of the forms 
of IMP1 is required for MYC mRNA stabilization. We wanted to test whether 
ΔN-IMP1 was specifically required for MYC mRNA stability due to E2 
stimulation. To test this, we “rescued” ΔN-IMP1 by expressing ΔN-IMP1 or an 
empty vector as a control in the sh5149 cells. We then performed the RNA 
stability assay with the rescue cell line. ΔN-IMP1 expression was able to 
rescue the MYC mRNA stabilization whereas empty vector-expressing cells 
were not (Figure 2.7). 
 We wanted to determine whether the loss of IMP1 also affected cell 
cycle progression and proliferation. Using the sh8079 and sh5149 and 
comparing them to shCtrl cells, loss of only FL-IMP1 showed a similar 
phenotype as shCtrl cells, however, sh5149 cells were unable to enter S 
phase and also had a proliferative defect (Figure 2.8). These data, taken 
together with the MYC mRNA stability defect, suggest that MYC stability may 
be require for cell cycle progression upon E2-stimulation. 
Phosphorylation of Tyrosine 260 of ΔN-IMP1 is Required for MYC mRNA 
Stability. 
SRC has previously been shown to regulate FL-IMP1 function through 
phosphorylation of tyrosine 396 in the context of β-actin mRNA (Hüttelmaier et 
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al., 2005). Given that our data suggested that SRC kinase activity is required 
for MYC mRNA stability and that ΔN-IMP1 was necessary for stabilization, we 
hypothesized that phosphorylation of this residue was required for ΔN-IMP1 to 
Figure 2.8: Loss of FL-IMP1 and DIMP1 results in a proliferation defect. 
(A) BrdU incorporation assay and (B) proliferation assay in shCtrl, sh8079, 
sh5149 knockdown MCF7 cells pretreated with vehicle or 1 µM SU11333 and 
stimulated with vehicle or 5nM E2. *=p<0.05 
 
stabilize MYC mRNA. To test this hypothesis, we generated a ΔN-IMP1 
mutant with tyrosine 260 (corresponding to the Y396 residue in FL-IMP1) 
mutated to phenylalanine to mimic a non-phosphorylated residue (Figure 2.9). 
We then expressed either wild-type ΔN-IMP1 or the Y260 mutant in the 
sh5149 knockdown cells. Introduction of a wild-type version of ΔN-IMP1 
resulted in an increased MYC mRNA half-life compared to the empty vector 
(Figure 2.9). Expression of the ΔN-IMP1-Y260F mutant was unable to rescue 
stabilization of MYC compared to the wild-type ΔN-IMP1, suggesting that 
phosphorylation of the tyrosine residue at 260 is required for increased MYC 
mRNA stability (Figure 2.9).  
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The sh5149 knockdown cells had previously shown a defect in cell 
cycle progression and proliferation, so we wanted to test what effect the 
Y260F mutant had on these phenotypes. Using the BrdU incorporation assay, 
our sh5149 knockdown cells were unable to progress in the cell cycle 
compared to shCtrl cells (Figure 2.9). If we expressed wild-type ΔN-IMP1 in 
the sh5149 knockdown cells, these cells could rescue the cell cycle and 
proliferation defects.  
 
Figure 2.9: Y260F mutant of DIMP1 is unable to rescue MYC mRNA 
stabilization in sh5149 knockdown cells. (A) Representative immunoblot of 
shCtrl, sh5149, DIMP1/sh5149, or DIMP1-Y260F/sh5149 MCF7 cells. (B) MYC 
mRNA stability assay in shCtrl, sh5149, DIMP1, and DIMP1-Y260F MCF7 cells 
pretreated with vehicle or 1 µM SU11333 and stimulated with vehicle or 5nM 
E2. After 60 min, cells were treated with 5 µM Actinomycin D to block 
transcription. (C) BrdU incorporation assay and (D) proliferation assay in 
shCtrl, sh5149, DIMP1, and DIMP1-Y260F MCF7 cells pretreated with vehicle 
or 1 µM SU11333 and stimulated with vehicle or 5nM E2. *=p<0.05 
 
However, in the cells where we expressed ΔN-IMP1-Y260F, we were unable 
to observe cells entering S phase or proliferating compared the wild-type ΔN-
IMP1 rescue cells, and they more resembled the sh5149 knockdown cells 
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(Figure 2.9). These data suggest that the phosphorylation of Y260 is required 
for MYC mRNA stability, and ultimately, cell cycle progression. 
Discussion 
The genomic effects after E2 stimulation have been widely studied, 
however, the non-genomic pathway is more poorly understood. The non-
genomic effects are thought to be acting via cytoplasmic signaling pathways 
potentially involving SRC, MAPK, PKC, and PI3K (Castoria et al., 2001; 
Lobenhofer et al., 2000). Our lab’s focus on SRC kinase has led us to explore 
the role of SRC kinase during E2-dependent signaling and proliferation in an 
ER-positive breast cancer model. We hypothesized that SRC was required for 
E2-dependent proliferation and aimed to further understand its potential role in 
non-genomic E2 signaling. 
 We found that SFKs were required for E2-dependent proliferation by 
using a small-molecule inhibitor of SFKs, SU11333. The MCF7 cells that we 
used expressed two SFKs, SRC and YES. The literature has suggested that 
SFKs have redundant roles based on data from SFK knockout mice (Lowell 
and Soriano, 1996). While src-/- mice only displayed a mild osteoclast 
phenotype, mice in which two or three ubiquitously expressed SFKs (SRC, 
YES, and FYN) are disrupted display severe phenotypes including embryonic 
lethality (Klinghoffer et al., 1999; Stein et al., 1994). Using shRNA-mediated 
SRC or YES knockdown cells, we found that SRC is required for E2-
dependent mitogenesis, whereas YES is not required. This is consistent with 
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data from the MMTV/PyVmT breast cancer mouse models in which full 
knockout (Guy et al., 1994) or mammary epithelial-specific knockout (Marcotte 
et al., 2012) of SRC have defects in mammary gland development, E2-
dependent cell cycle progression, and development of mammary tumors. Our 
findings are also consistent with data from the MMTV/PyVmT mice in yes-/- 
backgrounds that do not show any impairment of tumor formation as 
compared to wild-type mice (Guy et al., 1994). These data taken together 
suggest non-overlapping roles for SRC and YES in E2-dependent 
proliferation.  
 Our data suggest that SRC’s role in E2-dependent proliferation is to 
stabilize MYC mRNA levels. This is consistent with other reports suggesting 
that MYC mRNA levels are regulated post-transcriptionally due to E2 or 
growth factor stimulation (Blanchard et al., 1985; Bromann et al., 2005; Dean 
et al., 1986; Greenberg and Ziff, 1984; Kelly and Siebenlist, 1986; Kindy and 
Sonenshein, 1986; Nepveu et al., 1987; Santos et al., 1988). However, this 
conflicts with several studies that suggest that E2 stimulation induces 
transcription of MYC mRNA (Dubik et al., 1987; Dubik and Shiu, 1988; Shiu et 
al., 1993; Wang et al., 2011). There are a few explanations that could explain 
these conflicts. First, the E2 concentrations used for many experiments vary in 
some cases up to 50-fold from the doses that were used in this study (Dubik et 
al., 1987; Dubik and Shiu, 1988; Shiu et al., 1993), and increased 
concentrations of E2 may result in more pharmacological signaling than 
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physiological signaling. Another possibility arises from the frequent use of 
MCF7 cell line as a model for E2 signaling. Some publications have described 
variations in E2 response as well as expression profiles of different sources of 
MCF7 cells (Nugoli et al., 2003; Osborne et al., 1987). To support our findings 
for E2-dependent stabilization of MYC mRNA, we complemented the analyses 
in the MCF7 cells with analyses in the ZR-75-1 cells. 
 We identified ΔN-IMP1 to be expressed in several ER-positive breast 
cancer cell lines and necessary for MYC mRNA stability due to E2 stimulation. 
We found that ΔN-IMP1 is needed for MYC mRNA stability, but the 
mechanism behind how it is regulating mRNA stability is unknown. Preliminary 
experiments to immunoprecipitate (IP) ΔN-IMP1 were unsuccessful as the 
antibody that we used to detect it could not IP the protein (data not shown). 
This technical limitation has currently prevented us from testing whether SRC 
directly phosphorylates ΔN-IMP1 as well as performing an RNA-IP to test 
whether ΔN-IMP1 can interact with MYC mRNA. 
Little is known about the function of the truncated form since it was first 
identified (Fakhraldeen et al., 2015), and hints about its function are derived 
from studies involving the function of full length IMP1. FL-IMP1 contains six 
RNA binding domains including two RNA recognition motifs and four KH 
domains (Bell et al., 2013) while ΔN-IMP1 only retains the four KH domains 
(Fakhraldeen et al., 2015). ΔN-IMP1 also retains the tyrosine residue 
described to be phosphorylated by SRC and required for release of bACTIN 
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mRNA (Hüttelmaier et al., 2005). Our data suggests that this residue in ΔN-
IMP1 is important for MYC mRNA stability. The discrepancy between how 
SRC regulates mRNA binding to either IMP1 or ΔN-IMP1 may be an intrinsic 
feature of the target mRNA or differences between the isoforms. Supporting 
this hypothesis are several studies examining which KH domains are required 
for specific target mRNA binding. MYC mRNA has been found to likely require 
the first and second KH domains of IMP1 for binding (Barnes et al., 2015), 
bACTIN mRNA has been suggested to require the third and fourth KH 
domains for binding (Farina et al., 2003; Nicastro et al., 2017; Patel et al., 
2012) and the CD44 mRNA requires the fourth KH domain for IMP1 binding 
(Barnes et al., 2015). These data suggest that specific characteristics of the 
mRNA, possibly the sequence, are important for the function of IMP. IMP1 has 
been described to regulate a large cassette of target genes (i.e. MYC, 
bACTIN, CD44, IGF-II, MITF) via numerous functions (mRNA stability, mRNA 
localization, translational repression) (Bell et al., 2013). However, the overlap 
between target genes and function of full-length IMP1 and ΔN-IMP1 is 
completely unknown. Additionally, because many of the previous studies have 
looked at only the full-length form of IMP1, and many of the reagents used for 
studies can recognize both full-length and truncated IMP1, some of the 
published results may have results that are confounded by this isoform. While 
this study has suggested a potential role for ΔN-IMP1, many open research 
questions remain. Interestingly, we observed ∆N-IMP1 to be expressed in ER-
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positive breast cancer cell lines. ER-positive breast cancer cell lines may 
serve as a good model system for future studies. 
 In our orthotopic ER-positive breast cancer xenograft model, we found 
that inhibition of SFKs using saracatinib, a tyrosine kinase inhibitor that is 
somewhat selective for SFKs and ABL kinase, inhibited growth of tumors in 
mice. These data suggest that treating ER-positive breast cancer tumors with 
SRC inhibitors may be an effective strategy. Indeed, several studies have 
tested this in preclinical and clinical trials. A Phase II clinical trial using the 
kinase inhibitor, dasatinib (an SFK inhibitor with some selectivity also for KIT, 
PDGFR, and ABL), found an objective response rate (ORR) of 4% and a 
disease control rate (DCR) of 16% in hormone receptor (HR)-positive breast 
cancer patients suggesting limited benefits for patients (Mayer et al., 2011). 
Another Phase I/II study using dasatinib in combination with zoledronic acid for 
treatment of breast cancer bone metastasis found that 23% of patients 
showed partial response (PR) in bone metastases, and these patients all had 
HR-positive breast cancer (Mitri et al., 2016). Treatment of MMTV/PyVmT 
mice with bosutinib, a SRC/ABL kinase inhibitor, showed decreased tumor 
development and inhibition of growth of established tumors (Hebbard et al., 
2011). In a clinical trial using bosutinib in patients with locally advanced 
metastasis or metastatic breast cancer, progression free survival (PFS) at 16 
weeks was highest in the HR-positive patients (44 patients, 43%) and 4 HR-
positive patients had confirmed PR (Campone et al., 2012). 
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 Increased expression of SRC in ER-positive tumors (Elsberger, 2014; 
Ottenhoff-Kalff et al., 1992; Verbeek et al., 1996) taken with our data 
suggesting that both the E2 stimulus and SRC activity are required for 
proliferation, suggest potential benefits in combined ER and SRC inhibition. 
Several studies have studied this combination. Combined use of tamoxifen 
and saracatinib has been shown to synergistically inhibit anchorage 
independent growth of MCF7 cells (Herynk et al., 2006). SRC has also been 
suggested to be involved as a mechanism for anti-estrogen resistance. MCF7 
cells that were generated to be resistant to tamoxifen showed increased 
activated SRC levels (Hiscox et al., 2007). In a follow-up to this study, two ER-
positive cell lines were treated individually with either tamoxifen or saracatinib 
and in both cases, the cells acquired resistance to the inhibitors (Hiscox et al., 
2009). However, cells that were treated with combined tamoxifen and 
saracatinib treatment were all dead after 13 weeks and unable to acquire 
resistance to the inhibitors (Hiscox et al., 2009). Another study combined the 
aromatase inhibitor, anastrozole, with saracatinib to treat ER-positive 
xenografts of MCF7 cells engineered to express aromatase (Chen et al., 
2009). Saracatinib initially inhibited tumor growth, but tumors acquired 
resistance during the study. The combined saracatinib and anastrozole 
treatment was more effective than either inhibitor alone (Chen et al., 2009). 
Interestingly, the saracatinib-resistant tumors showed upregulation of MAPK 
and PI3K, two other kinases implicated in the non-genomic signaling pathway. 
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These data suggest that the non-genomic E2 signaling pathway play a role in 
resistance to anti-estrogen treatment. Further research into the effects of 
combined therapies in ER-positive breast cancer models is needed. 
Methods 
Cell Culture 
MCF7 cells (ATCC) were grown in IMEM supplemented with 10% FBS. 
ZR-75-1 (ATCC), T47D (ATCC), ZR-75-30, and SUM44PE (gift from Joe 
Gray) cells were grown in RPMI supplemented with 10% FBS. 293T cells were 
grown in DMEM supplemented with 10% FBS. For starvation prior to estrogen 
stimulation in the assays described below, cells were washed 1X in PBS and 
starved for 48 hours in starvation medium [phenol red-free IMEM, 0.5% 
charcoal, dextran stripped FBS (Hyclone)]. For pre-treatment with inhibitors, 
inhibitors were diluted into starvation medium and incubated for 2 hours prior 
to stimulation. All experiments were performed in the absence of antibiotics.  
 
Plasmids 
RNAi knockdown was performed using the pLKO.1 or pLKO.1-TetOn 
shRNA expression vectors. The RNAi consortium clone numbers for each of 
the shRNA constructs are: SRC (TRCN0000195339), YES 
(TRCN0000001609), IMP1 (TRCN0000075149), IMP1 (TRCN0000218079). 
Overexpression was performed by expressing the following cDNAs in the 
pCDH lentiviral vector: ΔN-IMP1. 
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Chemicals 
ICI182780 (Tocris Biosciences), Actinomycin D (Sigma-Aldrich), 
saracatinib (APExBio), SU11333 (Sanford|Burnham|Prebys Medical Research 
Institute), were used in pre-treatment of cells during starvation as described 
above. 
 
Bromodeoxyuridine (BrdU) Incorporation Assay 
Cells were plated at 60% confluency on glass coverslips in normal 
growth medium and allowed to grow overnight. The next morning cells were 
washed once with PBS and then placed in starvation medium. Cells were 
pretreated for 2 hours with 1 μM SU11333 or DMSO vehicle prior to 
stimulation. Cells were then treated with either ethanol or 5 nM estrogen (E2) 
with 5 µM BrdU for 18 hours. After treatment, cells were washed twice with 
cold PBS and fixed with ice-cold 1:1 methanol:acetone. Coverslips were then 
rehydrated in PBS for 15 minutes. Cells were permeabilized in 0.1% TX-100 in 
PBS for 10 minutes. Cells were then treated with 2N hydrochloric acid at 37C 
for 15 minutes. Coverslips were then washed 3x in PBS with rocking. 
Coverslips were blocked with 1% goat serum in PBS for 1 hour with rocking. 
Anti-BrdU (Millipore) antibody was used to detect incorporated BrdU 
(Millipore). Anti-mouse 488 secondary was used to visualize staining via 
immunofluorescence analysis. Vectashield containing DAPI was used to 
mount the coverslips and stain nuclei. 
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Proliferation Assays 
Cells were plated at 25 x 103 and viable cells were counted every 2 
days using the Countess II Automated Cell Counter (Thermo Fisher Scientific). 
 
Reagents and Antibodies for Immunoblotting 
The following commercial antibodies were used: anti-SRC [pY418] antibody 
(Invitrogen), anti-SRC (327) antibody (Abcam), anti-YES, anti-MYC (Y69) 
antibody (Abcam), anti-IMP1 antibody (Cell Signaling Technology), anti-
IGF2BP1 antibody (Sigma-Aldrich), anti-γ–tubulin antibody (Sigma-Aldrich), 
anti-actin (C-74) antibody (Sigma), and anti-BrdU (Millipore). For secondary 
antibodies, Alexa Fluor 680 goat anti-rabbit IgG (Invitrogen) or IR800 
(Rockland Immunochemicals) were used for immunoblotting.  
 
Immunoblotting 
Cell lysates were prepared by washing cells twice with cold Tris-
buffered saline (TBS) containing 100 μM Na3VO4 and then lysed in 50 mM 
Tris-HCl (pH 7.5), 250 mM NaCl, 1% Triton X-100, 50 mM NaF, 100 μM 
Na3VO4 and 1mM EDTA lysis buffer containing a dissolved complete Mini 
protease inhibitor tab (Roche Diagnostics). Supernatant of cell lysates was 
assayed for total protein content using the BCA protein assay (Thermo Fisher 
Scientific), and 50 μg of total protein per sample was separated in a 
polyacrylamide gel (Invitrogen). Membranes were scanned using an infrared 
imaging system (Odyssey; LI-COR Biosciences). 
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RNA Isolation and cDNA generation 
Trizol extraction of RNA was performed per manufacturer’s instructions. 
cDNA was generated using the SuperScript III First-Strand Synthesis System 
(Invitrogen) according to the manufacturer’s instructions. 
 
MYC mRNA Accumulation Assay 
Cells were starved and stimulated as described above. Post-E2 
stimulation, RNA was isolated at the indicated times, and cDNA was 
generated. To quantify the RNA accumulation, qPCR analysis was performed. 
For each sample, MYC mRNA was normalized independently to two different 
housekeeping genes (PPIA or RPLP0). Primers for analysis were used as 
previously described (Weidensdorfer et al., 2009). Time points for each 
condition were all normalized to time 0 for each condition. Representative 
experiments are shown. 
 
Transcriptional Run-on Assay 
To label transcripts, the Click-iT Nascent RNA Capture Kit (Invitrogen) 
was used and adapted for this assay. Cells were starved and stimulated as 
described above. Transcription was then paused by placing samples on ice at 
various time points post-stimulation. Intact nuclei were isolated at each time 
point for analysis. Labelled 5-ethyl Uridine (EU) were added; and samples 
were incubated at 37C to allow for elongation of initiated transcripts. EU will 
only be incorporated into these initiated transcripts. The EU is then biotinylated 
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and then collected using streptavidin beads. RNA is isolated off the beads and 
cDNA generated for qPCR analysis. 
 
RNA Stability Assay 
Cells were starved and stimulated as described above. Sixty minutes 
post E2- stimulation, cells were treated with 5 μM Actinomycin D to block 
transcription. At the indicated time points, RNA was isolated and cDNA 
generated for each condition. For each sample, MYC mRNA was normalized 
independently to two different housekeeping genes (PPIA or RPLP0). These 
genes were selected so that Actinomycin D treatment did not alter their 
expression. Time points for each condition were all normalized to time 0 for 
each condition. MYC mRNA half-life was then calculated for each of the 
conditions. To determine significance, one -way ANOVA and Tukey’s post-hoc 
tests were performed on the MYC mRNA half-life at the endpoint of the 
experiment to determine statistical significance. 
 
Orthotopic Mouse Xenograft Experiments 
Female, athymic nude mice were purchased from Jackson Laboratory. 
Mice were injected with a slow-release 17β-estradiol pellet (0.72 mg/pellet, 60-
day release from Innovative Research of America) by using a trochar. One 
week later, mammary fat pad injections in the number 4 mammary gland were 
carried out without clearing of the fat pad. Briefly, cells were harvested by 
trypsinization and resuspended in PBS (Invitrogen). For each cell line, the 
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mice were injected in a non-cleared mammary fat pad with 1x106 cells per 
animal in a volume of 100 μl [1:1 ratio with Matrigel (BD Biosciences)], and 
tumors were allowed to form with a diameter of up to 1 cm. Tumor onset was 
determined by physical palpation. Tumor growth was measured every 3-4 
days using calipers; both the longest (L) and shortest (S) measurements were 
recorded. Using these values, tumor volumes were calculated as follows: 
(L×S2) × 0.5, and expressed as mean volume ± SEM. Mice were sacrificed 
when the tumors reached a diameter of 1 cm, according to the Animal Care 
and Use Policy of OHSU. These experiments were repeated at least 3 times, 
using 5–10 mice per tumor group. One-way ANOVA, student’s t test, or 
Tukey’s post-hoc tests were performed on the tumor volume at the endpoint of 
the experiment to determine statistical significance as appropriate.  
 For inhibitor studies, once mice had measurable tumors of 50 mm3, 
treatment with 50 µl vehicle, ICI182870 (10 mg/Kg), or saracatinib (25 or 50 
mg/Kg) was injected intraperitoneally and tumor volume measured every three 
days. 
 
Statistical Analyses 
Statistical significance was determined by calculating the p-value (P) 
using the paired Student’s t test. P<0.05 was considered to be statistically 
significant. The numbers of samples (n) are indicated in each figure legend. 
For 2D, 3D, and tumor growth curves, area under the curve analysis was 
performed on the individual growth curves using the Area Under the Curve 
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(AUC) function in the GraphPad Prism software. Means and SEM were then 
calculated and Student’s t test or Tukey’s post-hoc test was used to determine 
significance. 
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Abstract 
The estrogen receptor (ER)-positive breast cancer subtype frequently 
expresses wild-type p53 unlike most tumor types. We hypothesized that the 
protein tyrosine kinase SRC could be inhibiting p53 in ER-positive breast 
cancer cells in a non-genomic E2 signaling pathway. We demonstrated that 
SRC is not required for cell cycle progression or proliferation in cells lacking 
p53 in vitro. In an MCF7 orthotopic xenograft model expressing SRC shRNA 
cells, we demonstrated that SRC is critical for initiation of xenografts 
independent of p53 expression. In established tumors, SRC inhibition by RNAi 
caused tumor regression in control tumors, but only decreased growth in p53-
knockdown tumors. However, in saracatinib treated xenografts, tumors 
responded regardless of p53 status. The p53 knockdown tumors, as well as in 
vitro cell lines showed a role for p53 in repressing expression of MYC. Upon 
knockdown of p53, we observed increased basal half-life of MYC without any 
changes in transcription. We also observed an increase in DN-IMP1 
expression, which we previously showed to be required for stabilization of 
MYC mRNA. Lastly using RNAi, we implicated MDM2 as a downstream 
effector of SRC signaling to inhibit p53. Mutation of SRC target tyrosines on 
MDM2 caused decreased proliferation. These data suggest a pathway where 
SRC inhibits p53 via MDM2, and p53 represses MYC mRNA leading to a cell 
cycle block. 
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Introduction 
 
Loss of p53 function is one of the most prevalent alterations in cancer. 
It has been suggested through its loss-of-function and gain-of-function effects, 
that it can be contributing for the majority, if not all, of Hanahan and 
Weinberg’s Hallmarks of Cancer (Hanahan and Weinberg, 2011). However, in 
some cancer types, as in estrogen receptor-positive (ER+) breast cancer (BC), 
wild-type p53 is often retained (Caleffi et al., 1994; Dumay et al., 2013). 
Because this loss of function seems to be a critical event in cancer 
development, it is hypothesized that cancer cells that express wild-type p53 
have some other mechanism of inhibiting p53 function. In some cases, 
increased expression or activating mutations of the p53 inhibitor, MDM2, can 
also result in loss of p53 function. 
 In addition to retaining wild-type p53, ER-positive breast cancer also 
expresses the protein tyrosine kinase, SRC, at high levels (Elsberger, 2014; 
Ottenhoff-Kalff et al., 1992; Verbeek et al., 1996). Several pieces of evidence 
hint at SRC playing a role in inhibiting p53 function. From our previous work, 
we have demonstrated that in fibroblasts and MEFs lacking functional p53, a 
requirement for SRC in cell cycle progression is abolished (Broome and 
Courtneidge, 2000). This suggests that SRC is potentially acting as an 
upstream inhibitor of p53 in response to growth factor stimulation. Despite 
these data, little research to our knowledge has been focused on the 
mechanism by which SRC could inhibit p53 activity. 
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 The most widely studied p53 inhibitor is the E3-ubiquitin ligase, MDM2. 
MDM2 ubiquitinates p53 which leads to sequestration from the nucleus and 
ultimately proteasomal degradation of p53 (Haupt et al., 1997; Honda et al., 
1997; Kruse and Gu, 2009; Kubbutat et al., 1997; Wu et al., 1993). MDM2 can 
also be phosphorylated by SRC and be converted into a NEDDylating enzyme 
that can inhibit p53 transcriptional activity (Batuello et al., 2015; Xirodimas et 
al., 2004). MDM2 is, itself, a p53 target gene, thus, negatively regulating its 
own expression (Wu et al., 1993). Another MDM family member, MDMX, has 
also been described as a p53 inhibitor functioning through direct binding to 
either p53 or MDM2 (Huang et al., 2011; Linares et al., 2003; Marine and 
Jochemsen, 2005; Waning et al., 2011). MDM2 and MDMX have been shown 
to be critical, non-redundant inhibitors of p53 evidenced by both MDM2 (Jones 
et al., 1995; Montes de Oca Luna et al., 1995) and MDMX (Parant et al., 2001) 
knockout mice presenting with embryonic lethality that can be rescued by 
concomitant loss of p53. While most function of MDM2 and MDMX has been 
studied during the DNA damage response, some evidence exists that they 
play roles in cell cycle inhibition (Gilkes et al., 2008). Both MDM2 and MDMX 
have been shown to be regulated by ABL kinase to regulate p53 although 
studies have shown both activation and inhibition of p53 downstream of ABL 
(Goldberg et al., 2002; Sionov et al., 2001; Sionov et al., 1999; Waning et al., 
2011; Zuckerman et al., 2009). Interestingly, ABL has also been shown to be 
downstream of SRC and required to overcome a cell cycle block during 
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mitogenesis (Furstoss et al., 2002). Taken together these studies suggest a 
potential role for MDM2 and MDMX in mitogenesis. 
Given that in fibroblasts, SRC may be inhibiting a p53 cell cycle block, 
and that MYC expression can overcome a SRC inhibition-mediated cell cycle 
block, it is interesting that a few studies suggest that p53 may be able to 
repress MYC mRNA expression. One study suggests that p53 is able to bind 
to the MYC promoter and represses MYC expression (Ho et al., 2005). 
Another study suggests that p53 may repress MYC via transcriptional 
regulation of miR-145 which directly targets MYC mRNA (Sachdeva et al., 
2009). Also in vascular smooth muscle cells, podosome formation is regulated 
via a SRC-p53-miR-145 pathway providing additional evidence for SRC 
inhibition of p53 (Quintavalle et al., 2010). 
ER-positive breast cancer provides a good model system for examining 
the role of SRC and p53 during cell cycle regulation. Insights from these 
studies are not only potentially applicable to therapeutic strategies, they are 
likely essential to understanding normal cell cycle regulation as well. Here, we 
examine the role of SRC overcoming a cell cycle block in ER-positive breast 
cancer. 
Results 
 
SRC is Required to Relieve a p53 Cell Cycle Block After E2 Stimulation.
  
We previously demonstrated that SRC was required for cell cycle 
progression, and we wanted to test whether this was mediated by relieving a 
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p53 cell cycle block similar to our published results in fibroblasts (Broome and 
Courtneidge, 2000). To test this using shRNA-mediated knockdown, we 
generated stable p53 (shTP53) and scrambled control (shCtrl) knockdown in 
MCF7 cells and then performed a BrdU incorporation assay after stimulating 
quiesced MCF7 cells with E2 (Figure 3.1). In shCtrl cells, after E2 stimulation, 
cells entered S phase and incorporated BrdU, and cell cycle entry was blocked 
in cells pre-treated with SU11333. However, in shTP53 knockdown cells, 
SU11333 was unable to block E2-dependent BrdU incorporation (Figure 3.1). 
Additionally, we performed a proliferation assay to assess the long-term 
effects of SFK inhibition in shTP53 cells (Figure 3.1). Here, the vehicle treated 
shCtrl and shTP53 cells grew at nearly the same rate. Pretreatment with 
SU11333, blocked proliferation in the shCtrl cells, however, in the shTP53 
cells, SU11333 was unable to block proliferation. To complement the SFK 
inhibitor experiment, we also generated individual shSRC or shTP53 
knockdown cells or double shSRC/shTP53 knockdown cells and assessed 
both BrdU incorporation and proliferation (Figure 3.1). Consistent with the 
inhibitor experiments, targeted knockdown of SRC was able to block S phase 
entry and proliferation, but was unable to block BrdU incorporation or 
proliferation in shTP53 cells. Taken together, the inhibitor and shRNA 
experiments suggested a role for SRC kinase activity to overcome a p53 block 
to S phase entry and proliferation due to E2.  
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 Because we used shRNA that potentially could have off-target effects, 
we wanted to further test the specific role of p53 by introducing mouse p53 in 
our shTP53 cells to test whether this was able to restore the cell cycle block 
upon SU11333 treatment (Figure 3.2). Indeed, in the shTP53 cells, SU11333 
 
Figure 3.1-Knockdown of p53 abolishes a requirement for SRC in E2-
dependent proliferation. (A) (left) Representative immunoblot of shCtrl and 
shp53 cell lysates. (right) BrdU incorporation assay and (B) proliferation assay 
in shCtrl and shp53 knockdown MCF7 cells pretreated with vehicle or 1 µM 
SU11333 and stimulated with vehicle or 5nM E2. (C) Representative 
immunoblot analysis of shCtrl, shSRC, shTP53, and shSRC/shTP53 double 
knockdown MCF7 cells. BrdU incorporation assay and (D) proliferation assay 
in shCtrl, shSRC, shTP53, and shSRC/shTP53 double knockdown MCF7 cells 
pretreated with vehicle or 1 µM SU11333 and stimulated with vehicle or 5nM 
E2. *=p<0.05 
 
was unable to block cell cycle progression. However, in the cells that also 
expressed mouse p53, we were able to block cell cycle progression, and 
ultimately proliferation, with SU11333 (Figure 3.2). These experiments suggest 
that p53 is necessary and required for the cell cycle block due to SRC 
inhibition in vitro. 
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Saracatinib Inhibits Tumor Growth of MCF7 Xenografts Regardless of 
Expression of p53.  
Our in vitro data suggested that SRC was required for E2-dependent 
cell cycle progression and proliferation in cells which expressed p53. As we 
previously demonstrated that inhibition of SRC activity with the SRC+ inhibitor, 
saracatinib, slowed or inhibited growth of MCF7 xenografts (Figure 2.1), we 
next wanted to test whether this also required p53 to be expressed in the 
tumor in vivo. Using nude mice, we implanted E2 pellets one week prior to 
injection of cells. For the cell preparation, we injected 100 µl containing a 1:1 
mixture of Matrigel and PBS resuspension of 1 x 106 of either shCtrl or 
shTP53 cells. Upon reaching 50 mm3, mice were randomized into either 
DMSO, ICI182870, or saracatinib treatment groups. We measured tumors 
every three days for several weeks. In the shCtrl cells, ICI182870-treated 
tumors regressed completely whereas saracatinib-treated mice showed a 
decrease in tumor growth relative to the DMSO treated tumors (Figure 3.3). 
Similar to the shCtrl tumors, the shTP53 tumors regressed upon treatment 
with ICI182870 (Figure 3.3) suggesting that E2 was required for tumor growth 
regardless of p53 expression in the tumor. Surprisingly, in the shTP53 cells 
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Figure 3.2: Re-expression of p53 in shTP53 knockdown cells restores a 
SFK-dependent cell cycle and proliferation block. (A) Representative 
immunoblot analysis of shCtrl, shTP53, and p53wt (rescue in shTP53) MCF7 
cells. (B) BrdU incorporation assay and (C) proliferation assay in shCtrl, 
shTP53, and p53wt MCF7 cells pretreated with vehicle or 1 µM SU11333 and 
stimulated with vehicle or 5nM E2. *=p<0.05. 
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treated with saracatinib, we observed a decrease in tumor growth similar to 
what we observed in the shCtrl cells (Figure 3.3). We hypothesize that this 
discrepancy may be due to using a SRC inhibitor suited for in vivo use 
(saracatinib) versus using the more selective inhibitor, SU11333, as in our in 
vitro studies. Several other targets in addition to SRC of saracatinib may 
confound the effects we observed in vivo (Green et al., 2009). Because our in 
vitro inhibitor studies were complemented with shRNA-mediate knockdown 
experiments, we aimed to test whether we could use stable knockdown cells 
to test our hypothesis in the orthotopic xenograft model. 
MCF7 Cells Require SRC Kinase Expression for Tumor Initiation in the 
Mouse Mammary Fat Pad. 
Using the orthotopic MCF7 xenograft model in nude mice to test the 
requirement for SRC in shTP53 knockdown cells using shRNA-mediated 
knockdown. Rather than using inhibitors, we injected either shCtrl cells, 
individual shSRC cells, individual shTP53 cells, or double shSRC/shTP53 
knockdown cells into the mouse mammary fat pad. We then measured tumors 
every three days. Compared to the shCtrl cells, the shTP53 cells grew at 
nearly the same rate generating large tumors during the course of the 
experiment (Figure 3.4). Mice injected with the shSRC cells did not develop 
tumors at any point during the experiment. Only 2/7 mice with the double 
shSRC/shTP53 knockdown tumors developed any tumors albeit very small 
around day 35 and only reach an average of 36 mm3 (Figure 3.4). We also 
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performed immunoblot analysis on some of the tumors (none of the shSRC 
tumors) to test that the knockdown persisted in these tumors (Figure 3.4). 
From these data, we concluded that SRC is likely required for MCF7 grafting 
of the orthotopic tumors. This role for SRC in tumor grafting appears to be 
independent of p53 expression in the tumor cells. All of our in vitro studies 
were performed using quiescent cells that were stimulated with E2. We 
hypothesized that this pathway is important in cells entering the cell cycle from 
a quiescent state. We performed the same experiment with the shCtrl, shSRC, 
shTP53, and shSRC/shTP53 cells, however, this time before resuspending 
them in PBS for injection, we serum starved them for two days. We again 
measured tumors every 3 days. No tumors were found in any mice until day 
14 (Figure 3.4). At this point, again the shCtrl and shTP53 cells grew at about 
the same rate for the duration of the experiment (Figure 3.4). Although there 
was a delay in tumor development, the rate of growth was similar to the 
previous experiment with non-quiesced cells Figure 3.4). Neither the shSRC or 
shSRC/shTP53 cells developed into tumors in any of the mice for the duration 
of the experiment (Figure 3.4).   
SRC Kinase is Required for Tumor Growth in Established MCF7 
Xenografts. 
Because we were unable to observe tumors in the shSRC or double 
shSRC/shTP53 injected mice, we aimed to overcome the grafting defect of the 
xenografts by using a doxycycline-inducible shSRC construct. We generated 
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stable cell lines doxycycline (Dox)-inducible (Tet-on) TOshCtrl or TOshSRC 
and combined them with stable shCtrl or shTP53 constructs (TOshCtrl/shCtrl, 
 
Figure 3.3- ICI182870 and saracatinib treatment inhibits growth of MCF7 
orthotopic xenografts. Mice were injected with (A) shCtrl or (B) shTP53 
knockdown MCF7 cells at Day 0. Once tumor reached 50 mm3, intraperitoneal 
treatment with DMSO, ICI182870, or saracatinib was performed every three 
days and tumors measured at the same time. *=p<0.05 
 
TOshSRC/shCtrl, TOshCtrl/shTP53, or TOshSRC/shTP53). To test the 
inducible knockdown in the cell lines, we first performed an in vitro time course 
by treating the cells with Dox. At 24 hours after treatment, we could still 
observe some expression of SRC, however, by 48 hours and persisting at 72 
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hours, we observed efficient knock down of SRC (Figure 3.5). After confirming 
the inducible knockdown of SRC, we implanted mice with E2 pellets and after 
a week injected the mice with the various combinations of inducible and stable 
shRNA expressing cell lines. We allowed the cells to grow until they reached 
100 mm3 and then randomized the mice into (-) Dox or (+) Dox chow. As a 
control for the inducible cell lines, we did not treat some mice with Dox (Figure 
3.5). All groups of mice in the (-) Dox group grew at the same rate suggesting 
that the inducible shRNA vectors had no basal “leaky” expression. The 
remainder of the mice were treated with Dox. Similar to what we observed in 
our study with constitutive double knockdown experiments, the 
TOshCtrl/shCtrl and the TOshCtrl/shTP53 cells grew at nearly the same rate 
(Figure 3.5). Upon doxycycline treatment TOshSRC/shCtrl cells began to 
regress until no measurable tumors were present (Figure 3.5). Interestingly, 
the TOshSRC/shTP53 tumors did not grow, but also did not regress as did the 
TOshSRC/shCtrl cells (Figure 3.5). In this inducible knockdown xenograft 
experiment, we observed that with loss of SRC in tumors that expressed p53 
lead to regression, but in tumors without p53, the tumors only have a growth 
defect.  
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Figure 3.4: Knockdown of SRC impairs development of MCF7 orthoptic 
xenografts. (A) Mice were injected with shCtrl, shSRC, shTP53, or 
shSRC/shTP53 double knockdown MCF7 cells at Day 0. Tumors were 
measured every three days. (B) Representative immunoblot of shCtrl, shTP53, 
and shSRC/shTP53 tumor lysates to validate knockdown in tumors. (C) The 
same experiment as (A) except cells were quiesced for 2 days before injection 
in the fat pad. *=p<0.05. 
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We previously described a role for SRC to induce MYC mRNA which 
leads to proliferation so we wanted to test whether this would correlate with 
the differences in tumor growth (Figure 2.3). We wanted to test whether MYC 
mRNA levels were altered in these tumors due to SRC inhibition, but also 
whether p53 expression influences MYC mRNA levels. We collected the 
tumors and isolated RNA in Trizol. We then performed qPCR analysis to 
detect MYC mRNA levels in the tumors. Compared to TOshCtrl/shCtrl tumors, 
TOshSRC/shCtrl tumors expressed significantly lower amounts of MYC mRNA 
(Figure 3.5). Interestingly, TOshCtrl/shTP53 tumors had significantly more 
MYC mRNA than in the control tumors (Figure 3.5). Lastly, the 
TOshSRC/shTP53 tumors had levels of MYC mRNA comparable to the control 
cells. The TOshCtrl/shCtrl tumors and the TOshCtrl/shP53 tumors grew at 
similar rates despite high levels of MYC mRNA expressed in the 
TOshCtrl/shTP53 tumors. Also, this implicates p53 as a potential inhibitor of 
MYC. Conversely, the TOshSRC/shTP53 tumors had similar levels of MYC 
mRNA to the TOshCtrl/shCtrl tumors, but had a significant growth defect. 
These data taken together suggest that MYC mRNA levels are not correlated 
with tumor growth and that other factors are contributing to tumor growth. 
p53 Inhibits MYC mRNA Expression. 
The xenograft experiments suggested a potential role for p53 in 
inhibiting MYC mRNA levels. Our previous results demonstrated a 
requirement for MYC in proliferation downstream of E2 and SRC (Figure 2.3), 
  
90 
 
Figure 3.5: Inhibition of SRC in established orthotopic xenografts leads 
to tumor regression in shCtrl cells and tumor stasis in shp53 cells. (A) 
Representative immunoblot analysis of TOshSRC/shCtrl and TOshSRC/shp53 
double knockdown MCF7 cells after in vitro treatment with doxycycline. (B) 
Mice were injected with TOshCtrl/shCtrl, TPOshCtrl/shTP53, TOshSRC/shCtrl 
and TOshSRC/shp53 double knockdown MCF7 cells. Once tumor reached 
100 mm3mice were randomly selected for the (top) no Dox or (bottom) Dox 
was performed every three days and tumors measured at the same time. (C) 
qPCR analyisis was performed on RNA from TOshCtrl/shCtrl, 
TPOshCtrl/shTP53, TOshSRC/shCtrl and TOshSRC/shp53 double knockdown 
MCF7 cells. *=p<0.05. 
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 and we wanted to test whether p53 was also part of this pathway regulating 
MYC mRNA expression. We first analyzed expression of MYC mRNA levels in 
the shTP53 cells. Consistent with the xenograft experiment, compared to 
shCtrl cells, we observed an increase in MYC mRNA (Figure 3.6). We next 
tested whether there was an increase in MYC protein as well as DN-IMP1 
(Figure 3.6), the RNA-binding protein that we found to be required to stabilize 
MYC mRNA (Figure 2.7). We found that both MYC and DN-IMP1 expression 
was increased in upon p53 knockdown (Figure 3.6). We next tested whether 
E2 stimulation of MYC mRNA was affected by p53 knockdown. Compared to 
shCtrl cells, we observed no differences in MYC mRNA accumulation in 
shTP53 cells with increasing concentrations of E2 or over time after 
stimulation with 5 nM E2 (Figure 3.6). We performed the same time course, 
but pretreated the cells with SU11333 to test whether the requirement for SRC 
in MYC mRNA accumulation was abrogated in cells lacking p53. SU11333 
blocked MYC mRNA induction compared to vehicle treated cells (Figure 3.6). 
However, comparing shTP53 cells to shCtrl cells, treatment with SU11333 was 
unable to block MYC mRNA accumulation (Figure 3.6). These data suggested 
that p53 likely inhibits MYC mRNA expression downstream of SRC.  
 We previously described a role for SRC in regulating MYC mRNA 
stability, not MYC transcription, upon E2 stimulation (Figure 2.5). We next 
tested whether p53 knockdown affected the transcription of MYC. We 
performed a transcriptional run-on assay in the shTP53 cells and assayed 
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Figure 3.6: Loss of p53 leads to increases in MYC mRNA and DIMP1 
independent of SFK activity. (A)qPCR analysis and (B) Representative 
immunoblot analysis of shCtrl and shTP53 cells. qPCR analysis of quiescent 
shCtrl or shTP53 knockdown MCF7 lines that were treated (C) with increasing 
[E2] or (D) with 5 nM over 90 min. (E) qPCR analysis of quiescent shCtrl or 
shTP53 knockdown MCF7 lines that were pretreated with vehicle or 1 µM 
SU11333 and treated with 5 nM over 90 min. *=p<0.05. 
 
 
transcription of MYC, PS2, and PPIA, as well as measured the cytoplasmic 
levels of these mRNAs at the coinciding time points (Figure 3.7). At the 
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transcriptional level, we observed an increase in transcription of PS2, but no 
change in either MYC or PPIA Figure 3.7). However, in looking at the 
cytoplasmic mRNA levels, we observed an increase in MYC mRNA levels in 
shTP53 cells as compared to shCtrl cells consistent with our previous 
experiments (Figure 3.7). 
Observing no increase in E2-dependent transcription of MYC mRNA in 
shTP53 cells, we next tested whether MYC mRNA stability was affected upon 
p53 knockdown. We stimulated cells with E2 and after one hour of stimulation, 
treated the cells with Actinomycin D to block transcription. We then quantified 
the MYC mRNA levels by qPCR after stopping transcription to calculate the 
half-life of MYC mRNA. In the shCtrl cells we observed a low basal half-life 
whereas the E2 stimulated cells showed significant increase in half-life that 
was abrogated upon pretreatment with SU11333 (Figure 3.7). Interestingly, in 
the shTP53 cells, we were unable to see an increase in half-life due to E2 as 
compared to the shCtrl cells (Figure 3.7). However, we do see an increased 
basal half-life of MYC mRNA as compared to the shCtrl cells, and a similar 
half-life is observed in the SU11333 treated cells (Figure 3.7). Upon 
knockdown of p53, it appears that the cells lose the ability to stabilize the MYC 
mRNA upon E2 stimulation, but instead maintain a higher basal stabilization of 
MYC mRNA. We could hypothesize that this may be due to the increased 
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Figure 3.7: Loss of p53 does not affect MYC transcription, but increases 
the stabilization of MYC mRNA. (A) Nuclear run-on assay of MCF7 cells 
treated with E2 over a time course. (B) Cytoplasmic fractions from the same 
samples as the nuclear run on assay in (A). (C) MYC mRNA stability assay in 
shCtrl and shp53 knockdown MCF7 cells pretreated with vehicle or 1 µM 
SU11333 and stimulated with vehicle or 5nM E2. After 60 min, cells were 
treated with 5 µM Actinomycin D to block transcription. *=p<0.05. 
 
DN-IMP1 expression observed in the p53 knockdown cells. These data are 
consistent with a model that increased expression of MYC mRNA is due to an 
increase in the basal half-life of MYC mRNA. 
Loss of MDM2 is Lethal in MCF7 Cells Expressing Wild-type p53.    
Much of the data presented here is consistent with SRC acting as an 
upstream inhibitor of a p53 cell cycle block. However, it is unknown how SRC 
inhibits p53. A likely candidate to act downstream of SRC is MDM2, a known 
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inhibitor of p53. To test this hypothesis, we generated MDM2 knockdown cells 
to test whether MDM2 was required for E2-dependent cell cycle progression 
and proliferation. Upon lentiviral transduction of the shMDM2 construct, we 
observed massive cell death, killing all cells within 48 hours. We attempted to 
conduct some experiments within this time frame. We tested the knockdown of 
MDM2 using immunoblot analysis and showed efficient knockdown 24 hours 
after transduction. We then performed a BrdU assay to test whether MDM2 
was required for cell cycle progression (Figure 3.8). While the shCtrl cells 
entered S phase, shMDM2 cells were significantly blunted in their ability to 
enter S phase. Interestingly, if we pretreated the cells with SU11333, there 
was no further decrease in cells incorporating BrdU suggesting that they may 
be involved in the same pathway (Figure 3.8). However, in this assay many of 
the cells were clearly stressed. This finding that we had difficulty generating 
MDM2 knockdown lines in consistent with previous studies where MDM2 
knockdown was attempted in cells expressing wild-type p53. Previous studies 
have demonstrated that in cells expressing wild-type p53, inhibition of MDM2 
often results in stabilization of p53 and activation of an apoptotic response 
(Jones et al., 1995; Montes de Oca Luna et al., 1995). To test whether this 
may be why our cells were dying, using lentivirus we generated stable shCtrl 
cells, shMDM2 cells, shTP53 cells, and double shMDM2/shTP53 cells, and 
assessed the efficiency of the knockdown (Figure 3.8). 
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Figure 3.8: Loss of MDM2 causes cell death unless combined with loss 
of p53. (A) (left) Representative immunoblot analysis of shCtrl and shMDM2 
knockdown MCF7 cells.  (right) BrdU incorporation assay in shCtrl and 
shMDM2 knockdown MCF7 cells pretreated with vehicle or 1 µM SU11333 
and stimulated with vehicle or 5nM E2. (B) (left)Representative immunoblot 
analysis of shCtrl, shMDM2, shTP53, shMDM2/shTP53. (right) Proliferation 
assay in shCtrl, shSRC, shTP53, and shSRC/shTP53 double knockdown 
MCF7 cells pretreated with vehicle or 1 µM SU11333 and stimulated with 
vehicle or 5nM E2. *=p<0.05. 
 
We then conducted a proliferation assay with these stable knockdown lines. 
Similar to what we observed before, the shCtrl and shTP53 cell lines grow at 
similar rates. The shMDM2 cells decreased in number rapidly following 
transduction (Figure 3.8). However, the shMDM2/shTP53 knockdown cells 
grew at the same rate as the shCtrl cells (Figure 3.8). This suggested that loss 
of p53 in this pathway rescues cells from the proliferative defect or induction of 
apoptosis due to loss of MDM2. 
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Phosphorylation of Y281 and Y302 on MDM2 Are Required for 
Proliferation in MCF7 Cells. 
 A recent report linked SRC phosphorylation of MDM2 to inhibition of 
p53’s transcriptional activity (Batuello et al., 2015). There are 5 tyrosine 
phosphorylation sites on MDM2 that have been demonstrated to be 
phosphorylated by either SRC (2 sites, Y281, Y302) or the tyrosine kinase 
ABL (3 sites, Y276, Y394, Y405). We focused on these sites because both 
SRC and ABL have been implicated in inhibition of p53 in the context of 
fibroblast mitogenesis (Broome and Courtneidge, 2000; Furstoss et al., 2002). 
Because we could not generate stable knockdown lines to then rescue 
expression with the phospho-mutants, we opted to overexpress several 
phospho-mutants in MCF7 cells expressing endogenous MDM2. We 
generated constructs corresponding to wild-type MDM2 (wt), the 2 SRC 
phosphotyrosines (2YF), the 3 ABL phosphotyrosines (3YF), and all 5 of these 
tyrosines (5YF). We recognize that overexpression of these mutants in cells 
with endogenous MDM2 may confound some of our results, but given the 
technical limitations of using the MDM2 knockdown cells, we may gain insights 
from these experiments. Upon transfection of these constructs, within 24 hours 
all of the 3YF and 5YF transfected cells were dead, and we, therefore, could 
not conduct any functional analyses on these cells (data not shown). This 
suggested that the 3 ABL phosphotyrosines are may be important for 
suppression of apoptosis. We performed immunoblot analysis on the empty 
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vector, wt, and 2YF overexpressing cells. Compared to the empty vector 
expressing cells, the wild-type expressing cells had a slightly decreased 
expression of MDM2 (Figure 3.9). This could possibly be due to a highly 
regulated negative feedback loop between MDM2 and p53. In the 2YF mutant, 
we observed increases in both MDM2 and p53 protein (Figure 3.9) This 
suggested that the 2YF mutant may have decreased ability to regulate p53 
levels. 
 We next wanted to test the mutants in functional assays. We first tested 
the effects of the mutants in the BrdU incorporation assay. There is a 
significant decrease in BrdU incorporation in the MDM2-wt overexpressing 
cells compared to the empty vector control (Figure 3.9). However, the 2YF 
mutant shows no change in BrdU incorporation relative to overexpressing 
MDM2-wt (Figure 3.9). We next looked at longer term proliferation, and 
observe that the MDM2-wt overexpressing cells grow relatively similar to the 
empty vector control. Unlike the BrdU assay, the 2YF cells proliferate slower 
than the empty vector or MDM2-wt overexpressing cells (Figure 3.9). These 
data taken together suggest that the two tyrosine residues suggested to be 
phosphorylated by SRC may be required for long term proliferative effects, but 
not acute S phase entry that we have observed upon SRC inhibition. This 
suggested that SRC is likely regulating other factors needed for proliferation, 
such as SRC phosphorylation of DN-IMP1. While not exhaustive, these  
 
  
99 
 
Figure 3.9: Overexpression of MDM2 Y281/302F mutant leads to 
increased p53 expression and a decrease in proliferation.  (A) 
Representative immunoblot of empty vector, MDM2-wt, and MDM2-2YF. (B) 
BrdU incorporation assay and (C) proliferation assay in empty vector, MDM2-
wt, and MDM2-2YF overexpressing MCF7 cells pretreated with vehicle or 1 
µM SU11333 and stimulated with vehicle or 5nM E2. *=p<0.05. 
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experiments offer some hints that MDM2 may act as a potential mediator of a 
SRC and p53 signaling axis. 
Discussion 
 
In this study, we aimed to characterize a potential role for SRC to inhibit 
p53 in the context of ER-positive breast cancer. Knockdown of p53 abolished 
the requirement for SRC in cell cycle progression and proliferation in vitro after 
E2 stimulation, and we also demonstrated that overexpression of mouse p53 
could rescue the cell cycle block. Studies from our lab and others have 
suggested that growth factor signaling inhibits a p53 cell cycle block (Broome 
and Courtneidge, 2000; Lei et al., 2011; Leri et al., 1999; Quintavalle et al., 
2010; Ries et al., 2000; Shaulian et al., 1997), and the current study is, to our 
knowledge, the first that suggests this is also true after E2 stimulation. This is 
particularly interesting in the context of ER-positive breast cancer because 
unlike most cancer types, p53 is rarely inactivated by mutation in ER-positive 
breast cancer (Caleffi et al., 1994; Dumay et al., 2013). This study suggests 
that activation of SRC is a mechanism to inactivate p53. 
  While our in vitro data suggests that SRC is not required for 
proliferation in cells lacking p53, the in vivo xenografts studies are a bit more 
complex. MCF7 cells expressing constitutive knockdown of SRC are unable to 
form tumors at an orthotopic site in nude mice regardless of p53 expression in 
the cells. This suggests that SRC is required for initial grafting of the tumor 
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cells in the mammary fat pad. These data are consistent with several mouse 
models where SRC is disrupted. An observed defect in ER signaling in the src-
/- mouse is consisted with our finding (Kim et al., 2005). MCF7 cells have been 
shown to require supplemental E2 when being grown as xenografts in mice. 
Disruption of SRC either genetically, as in the knockout mouse, or via shRNA-
mediated knockdown is effectively inhibiting the E2 signaling pathway required 
for MCF7 tumor xenografts to form. Our data are also consistent with a role for 
SRC in the MMTV/PyVmT breast cancer model crossed with a germline SRC 
knockout (Guy et al., 1994) where it has been shown to inhibit tumor 
development as compared to the wild-type mice. The xenografts studies 
where we used inducible SRC knockdown to test whether SRC was required 
for established xenograft growth showed that in cells lacking p53, SRC 
knockdown seemed to suppress growth of the tumor whereas in cells 
expressing p53, SRC knockdown caused regression of tumors. This finding 
suggests that tumors that express p53 may respond better to SRC inhibition 
than tumors lacking p53 or expressing inactivated mutant p53. 
 While no clinical trials have previously utilized p53 status as a 
biomarker for responsiveness to SRC inhibitors, several preclinical and clinical 
trials in breast cancer have suggested that multi-targeted kinase inhibitors that 
inhibit SRC, including dasatinib (Mayer et al., 2011; Mitri et al., 2016) and 
bosutinib (Campone et al., 2012; Hebbard et al., 2011) may be effective in 
hormone receptor (HR)-positive breast cancer patients. While correlative, HR-
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positive breast tumors typically express wild-type p53 (Caleffi et al., 1994; 
Dumay et al., 2013). Most of the clinically approved kinase inhibitors while 
“selective” for SRC, often inhibit a number of other kinases. The off-target 
effects of inhibitors can potentially confound experimental results. 
While the SRC knockdown experiments are consistent with the rest of 
our in vitro experiments and published findings, the results of the experiment 
where we used saracatinib as an inhibitor of SRC activity in tumors with or 
without p53 conflict with most of our other findings. One explanation for this 
discrepancy could be due to off-target effects of saracatinib. In addition to 
SFKs, saracatinib can also potentially inhibit ABL, EGFR, KIT at IC50 values 
near to those of SFKs (Green et al., 2009). Of these kinases, ABL has been 
suggested to both inhibit (Carr et al., 2016; Waning et al., 2011) and activate 
p53 (Sionov et al., 2001; Sionov et al., 1999; Zuckerman et al., 2009) via 
interactions with MDM2 and MDMX. ABL has also been described to be 
activated by SRC after PDGF stimulation in fibroblasts (Furstoss et al., 2002), 
however, it is unclear what downstream effectors SRC and ABL may have in 
common. Thus, dual inhibition may have a confounding effect as compared to 
individual inhibition of either kinase alone. An additional explanation could be 
due to the systemic effects of saracatinib in the mouse and on the tumor 
microenvironment in the mammary fat pad. We chose not to use the SU11333 
inhibitor used in the in vitro studies in the mouse studies for two reasons. First, 
the pharmacokinetics and pharmacodynamics of the inhibitor are unknown in 
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mice. Second, we opted to use a clinically available inhibitor to be more 
relevant as a preclinical model. While the in vivo inhibitor study was somewhat 
confounding, the knockdown studies demonstrated a clear role for SRC in 
inhibiting p53 function. 
Our finding that inhibition of p53 led to increases in MYC mRNA 
suggests a pathway wherein p53 is repressing MYC mRNA expression. Our 
analyses suggest that this is by increasing the basal half-life of MYC mRNA, 
rather than inducing transcription. Several possible mechanisms for the 
increased basal stability of MYC mRNA due to p53 exist. First, we showed that 
p53 is also repressing DN-IMP1 which we previously showed to be required to 
stabilize MYC mRNA. A second RNA-binding protein that has been involved in 
MYC mRNA destabilization, tristetraprolin (Marderosian et al., 2006; 
Rounbehler et al., 2012), has also been shown to be induced by p53 (Lee et 
al., 2013). Another potential mechanism is via p53 regulation of miRNAs (Feng 
et al., 2011). One study has suggested that miR-145 is regulated by p53 and 
MYC has been demonstrated to be a direct target of miR-145 (Sachdeva et 
al., 2009). Work from our lab has also found that miR-145 is also regulated 
downstream of SRC and p53 in vascular smooth muscle regulation of 
podosomes (Quintavalle et al., 2010). Some evidence also exists that p53 can 
also bind to the MYC promoter and repress its translation (Ho et al., 2005). 
While we did not observe increased transcription in p53 knockdown cells, our 
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finding is consistent with p53 repressing MYC via destabilization of the MYC 
mRNA 
While we can potentially implicate MDM2 as an inhibitor of p53 
downstream of SRC for cell cycle progression, many questions remain 
surrounding this pathway. Technical limitations involving induced cell death 
upon MDM2 knockdown complicate many of our experiments. While 
concomitant knockdown of MDM2 and p53 may allow cells to grow, they do 
not allow us to cleanly test our hypothesis. Inhibition of MDM2 in cells which 
express wild-type p53 often lead to apoptosis making it difficult to observe cell 
cycle effects. Introduction of the SRC and ABL tyrosine mutants of MDM2 
suggest that ABL phosphorylation is important in suppressing cell death. The 
SRC phospho-mutants proliferate slower than control cells, but because these 
mutants are expressed in cells with endogenous MDM2 the phenotypes of the 
mutants may be shielded. Because modulation of MDM2 itself seems to be 
detrimental to cell survival, this hypothesis may need to be tested using 
downstream effectors of MDM2. As SRC has been found to convert MDM2 
from a ubiquitin ligase to a neddylating enzyme (Batuello et al., 2015), 
additional studies may conduct mutational analysis of the putative p53 
neddylation sites to test whether the mutations affect cell cycle progression. 
Additionally, CRISPR deletion of one allele of MDM2 or substitution of one 
wild-type allele for a mutant allele may be a way to observe dose dependent 
responses to MDM2 modulation without killing the cells. The role of MDMX 
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also needs to be further studied in the context of SRC and cell cycle inhibition. 
Because MDM2 and MDMX are both critical inhibitors of p53 (Huang et al., 
2011; Kruse and Gu, 2009; Kubbutat et al., 1997; Marine and Jochemsen, 
2005; Wang et al., 2011), however, they have been shown to have non-
redundant roles as MDMX lacks E2 ligase activity. Additional studies need to 
further explore these two p53 inhibitors as mediators of SRC-dependent p53 
inhibition. 
 
Methods 
Cell Culture 
MCF7 cells (ATCC) were grown in IMEM supplemented with 10% FBS. 
For starvation prior to estrogen stimulation in the assays described below, 
cells were washed 1X in PBS and starved for 48 hours in starvation medium 
[phenol red-free IMEM, 0.5% charcoal, dextran stripped FBS (Hyclone)]. For 
pretreatment with inhibitors, inhibitors were diluted into starvation medium and 
incubated for 2 hours prior to stimulation. All experiments were performed in 
the absence of antibiotics.  
  
Plasmids 
RNAi knockdown was performed using the pLKO.1 or pLKO.1-TetOn 
shRNA expression vectors. The RNAi consortium clone numbers for each of 
the shRNA constructs are: SRC (TRCN0000195339), TP53 
(TRCN0000003753), MDM2 (TRCN0000355726). Overexpression was 
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performed by expressing the following cDNAs in the pCDH lentiviral vector: 
ΔN-IMP1; MDM2. 
 
Chemicals 
Estrogen, (Sigma-Aldrich), ICI182780 (Tocris Biosciences), 
Actinomycin D (Sigma-Aldrich), saracatinib (APExBio), SU11333 
(Sanford|Burnham|Prebys Medicinal Chemistry Core), were used as described 
above. 
 
Bromodeoxyuridine (BrdU) Incorporation Assay 
Cells were plated at 60% confluency on glass coverslips in normal 
growth medium and allowed to grow overnight. The next morning cells were 
washed once with PBS and then placed in starvation medium. Cells were 
pretreated for 2 hours with 1 μM SU11333 or DMSO vehicle prior to 
stimulation. Cells were then treated with either ethanol or 5 nM estrogen (E2) 
with 5 µM BrdU for 18 hours. After treatment, cells were washed twice with 
cold PBS and fixed with ice-cold 1:1 methanol:acetone. Coverslips were then 
rehydrated in PBS for 15 minutes. Cells were permeabilized in 0.1% TX-100 in 
PBS for 10 minutes. Cells were then treated with 2N hydrochloric acid at 37C 
for 15 minutes. Coverslips were then washed 3x in PBS with rocking. 
Coverslips were blocked with 1% goat serum in PBS for 1 hour with rocking. 
Anti-BrdU (Millipore) antibody was used to detect incorporated BrdU 
(Millipore). Anti-mouse 488 secondary (was used to visualize staining via 
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immunofluorescence analysis. Vectashield containing DAPI was used to 
mount the coverslips and stain nuclei. 
 
Proliferation Assays 
Cells were plated at 25 x 103 and viable cells were counted every 2 
days using the Countess II Automated Cell Counter (Thermo Fisher Scientific). 
 
Reagents and Antibodies for Immunoblotting 
The following commercial antibodies were used: anti-SRC (327) 
antibody (Abcam), anti-MYC (Y69) antibody (Abcam), anti-IGF2BP1 antibody 
(Sigma-Aldrich), anti-p53 (DO-1) antibody (Santa Cruz Biotechnology), anti-
MDM2 (SMP14) antibody (Santa Cruz Biotechnology), anti-MDM2 (C-18) 
antibody (Santa Cruz Biotechnology), anti-γ–tubulin antibody (Sigma-Aldrich), 
anti-actin (C-74) antibody (Sigma), and anti-BrdU (Millipore). For secondary 
antibodies, Alexa Fluor 680 goat anti-rabbit IgG (Invitrogen) or IR800 
(Rockland Immunochemicals) were used for immunoblotting.  
 
Immunoblotting 
Cell lysates were prepared by washing cells twice with cold Tris-
buffered saline (TBS) containing 100 μM Na3VO4 and then lysed in 50 mM 
Tris-HCl (pH 7.5), 250 mM NaCl, 1% Triton X-100, 50 mM NaF, 100 μM 
Na3VO4 and 1mM EDTA lysis buffer containing a dissolved complete Mini 
protease inhibitor tab (Roche Diagnostics). Supernatant of cell lysates was 
assayed for total protein content using the BCA protein assay (Thermo Fisher 
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Scientific), and 50 μg of total protein per sample was separated in a 
polyacrylamide gel (Invitrogen). Membranes were scanned using an infrared 
imaging system (Odyssey; LI-COR Biosciences). 
 
RNA Isolation and cDNA generation 
Trizol extraction of RNA was performed per manufacturer’s instructions. 
cDNA was generated using the SuperScript III First-Strand Synthesis System 
(Invitrogen) according to the manufacturer’s instructions. 
 
MYC mRNA Accumulation Assay 
Cells were starved and stimulated as described above. Post-E2 
stimulation, RNA was isolated at the indicated times, and cDNA was 
generated. To quantify the RNA accumulation, qPCR analysis was performed. 
For each sample, MYC mRNA was normalized independently to two different 
housekeeping genes (PPIA or RPLP0). Primers for analysis were used as 
previously described (Weidensdorfer et al., 2009). Time points for each 
condition were all normalized to time 0 for each condition.  
 
Transcriptional Run-on Assay 
To label transcripts, the Click-iT Nascent RNA Capture Kit (Invitrogen) 
was used and adapted for this assay. Cells were starved and stimulated as 
described above. Transcription was then paused by placing samples on ice at 
various time points post-stimulation. Intact nuclei were isolated at each time 
point for analysis. Labelled 5-ethyl Uridine (EU) and placed samples at 37C to 
  
109 
allow for elongation of initiated transcripts. EU will only be incorporated into 
these initiated transcripts. The EU is then biotinylated and then collected using 
streptavidin beads. RNA is isolated off the beads and cDNA generated for 
qPCR analysis. 
 
RNA Stability Assay 
Cells were starved and stimulated as described above. Sixty minutes 
post E2- stimulation, cells were treated with 5 μM Actinomycin D to block 
transcription. At the indicated time points, RNA was isolated and cDNA 
generated for each condition. For each sample, MYC mRNA was normalized 
independently to two different housekeeping genes (PPIA or RPLP0). These 
genes were selected so that Actinomycin D treatment did not alter their 
expression. Time points for each condition were all normalized to time 0 for 
each condition. MYC mRNA half-life was then calculated for each of the 
conditions. To determine significance, one -way ANOVA and Tukey’s post-hoc 
tests were performed on the MYC mRNA half-life at the endpoint of the 
experiment to determine statistical significance. 
 
Orthotopic Mouse Xenograft Experiments 
Female, athymic nude mice were purchased from Jackson Laboratory. 
Mice were injected with a slow-release 17β-estradiol pellet (0.72 mg/pellet, 60-
day release from Innovative Research of America) by using a trochar. One 
week later, mammary fat pad injections in the number 4 mammary gland were 
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carried out without the clearing of the fat pad. Briefly, cells were harvested by 
trypsinization and resuspended in PBS (Invitrogen). For each cell line, the 
mice were injected in a non-cleared mammary fat pad with 1x106 cells per 
animal in a volume of 100 μl [1:1 ratio with Matrigel (BD Biosciences)], and 
tumors were allowed to form with a diameter of up to 1 cm. Tumor onset was 
determined by physical palpation. Tumor growth was measured every 2–3 
days using calipers; both the longest (L) and shortest (S) measurements were 
recorded. Using these values, tumor volumes were calculated as follows: 
(L×S2) × 0.5, and expressed as mean volume ± SEM. Mice were sacrificed 
when the tumors reached a diameter of 1 cm, according to the Animal Care 
and Use Policy of OHSU. These experiments were repeated at least 3 times, 
using 5–10 mice per tumor group. One-way ANOVA, student’s t test, or 
Tukey’s post-hoc tests were performed on the tumor volume at the endpoint of 
the experiment to determine statistical significance as appropriate.  
For inhibitor studies, once mice had measurable tumors of 50 mm3, 
treatment with 50 µl vehicle, ICI182870 (10 mg/Kg), or saracatinib (25 mg/Kg) 
was injected intraperitoneally and tumor volume measured every three days. 
For the doxycycline-inducible shRNA-expressing cells, tumors were 
allowed to either 100 or 200 mm3 before being placed on chow with 0.2% 
(2000 ppm) doxycycline (Test Diet). Tumors were then measured as described 
above until control animals reached a diameter of 1 cm. 
 
Statistical Analyses 
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Statistical significance was determined by calculating the p-value (P) 
using the paired Student’s t test. P<0.05 was considered to be statistically 
significant. The numbers of samples (n) are indicated in each figure legend. 
For 2D, 3D, and tumor growth curves, area under the curve analysis was 
performed on the individual growth curves using the Area Under the Curve 
(AUC) function in the GraphPad Prism software. Means and SEM were then 
calculated and Student’s t test  and Tukey’s post-hoc test were used to 
determine significance. 
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New insights into non-genomic E2 signaling are beginning to show the 
many complexities of E2 signaling. As has been discussed, much of the 
research on E2 signaling has focused on the intrinsic DNA-binding and 
transcriptional role of the estrogen receptor (ER). However, our data 
demonstrated a role for SRC in mediating E2-dependent proliferation 
independent of transcription. SRC stabilized MYC mRNA upon E2 stimulation. 
Global analysis of E2-dependent gene expression should be conducted to 
uncover which E2 genes are being regulated by transcription versus mRNA 
stabilization. Our lab has previously looked at gene expression in quiescent 
fibroblasts that were pretreated with different kinase inhibitors, and then 
stimulated with PDGF. Using microarrays, we observed several different 
pathways acting downstream of PDGF, with distinct gene signatures that were 
being regulated by SRC, MAPK, or PI3K (Bromann et al., 2005). It would be 
interesting to test whether these pathways that have also been implicated in 
non-genomic E2 signaling pathways regulate similar target genes. 
 We found that SRC stabilized MYC mRNA via ΔN-IMP1. The 
mutagenesis experiments suggest that this is via phosphorylation of Y260, 
however it remains to be tested whether it is phosphorylated directly by SRC. 
We are not sure how generalizable this mechanism is for potential SRC 
stabilization of other mRNAs and how dependent the stabilization is on ΔN-
IMP1. Additional studies are needed to test what genes are being regulated by 
both SRC and ΔN-IMP1.  
  
119 
  This study suggested one function for ΔN-IMP1, however, little is 
known about this RNA-binding protein outside of inferences from studies of the 
full-length protein. ΔN-IMP1 lacks the first two RNA binding domains (RNA 
recognition motifs, RRMs) that are found in IMP1, however, the 4 KH domains 
are present (Fakhraldeen et al., 2015). This lack of RNA-binding domains 
presumably translates to changes in the specificity of target mRNAs that ΔN-
IMP1 can bind relative to IMP1. Interestingly, our data suggested that ΔN-
IMP1 likely retains the ability to bind MYC mRNA, however, the antibody used 
to detect ΔN-IMP1 is unable to immunoprecipitate the protein to test for a 
direct interaction.  
The mechanisms of regulation of ΔN-IMP1 are unknown, however 
several experiments from this study suggest some possibilities. We 
determined that SRC phosphorylation of ΔN-IMP1 promotes MYC mRNA 
stability which has not been shown previously. A more exhaustive analysis of 
how SRC phosphorylation potentially regulates other FL- or ΔN-IMP1 targets 
is needed. The expression pattern of DN-IMP1 in tissues is also largely 
unknown. The full-length form of this protein had been suggested to have an 
oncofetal expression pattern, so further expression analysis of ΔN-IMP1 
expression is needed and currently limited by lack of a specific antibody to that 
isoform. The current reagents used to study IMP1 will detect either only the 
full-length form or both forms, thus, the truncated form is likely being 
misreported. Currently, RNA expression or immunoblotting studies are the 
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only option for differentiating between the two forms. Several 
immunohistochemical expression studies will need to be revisited to see which 
isoforms are being expressed and which isoform are necessary for previous 
findings (Ioannidis et al., 2004; Ioannidis et al., 2003; Ioannidis et al., 2005; 
Ioannidis et al., 2001; Köbel et al., 2007).  
This study also suggests a potential mechanism of regulation of the 
gene. We also demonstrated that upon p53 loss, there was increased 
expression of ΔN-IMP1. ΔN-IMP1 is expressed from a novel promoter found in 
the second intron of the IGF2BP1 gene. This may implicate p53 as a 
transcriptional repressor of DN-IMP1. We also observed that loss of p53 
increased basal MYC mRNA stability, and we hypothesize that this may be 
due to the increased expression of DN-IMP1. From our data, we suggest that 
increased expression is also at the post-transcriptional level. As stated in 
previous chapters, p53 appears to suppress MYC mRNA stabilizers (ΔN-
IMP1, TTP) which could lead to decreases in MYC mRNA. An intriguing 
thought is that p53 regulating a cassette of miRNAs regulating global RNA 
stability. Previous studies have found that p53 also inhibits MYC mRNA via 
regulation of miR-145 which directly inhibits MYC mRNA stability (Sachdeva et 
al., 2009), Work from our lab has shown that miR-145 is also suppressed by 
SRC inhibition of p53 (Quintavalle et al., 2010). While SRC may be mediating 
acute MYC mRNA levels via DN-IMP1, p53 may be regulating basal expression 
of MYC mRNA via miRNA control. SRC suppression of p53 function could 
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lead to long-term miRNA deregulation lead to a “pro-tumorigenic” signaling 
environment. 
 Suppression of wild-type p53 function by SRC is an important finding. 
First, studies should be conducted in other cancer types that commonly harbor 
wild-type p53 to see if SRC is upregulated in those tumors as well, and if SRC 
inhibits p53 in those tumors. The data in this study suggest that SRC inhibitors 
should be targeted towards patients that retain wild-type p53, such as ER-
positive breast cancer patients. Our studies have primarily shown SRC 
inhibition in cells with p53 to be cytostatic. While this would be beneficial to 
patients, additional therapies may want to be combined because cancer 
clinical success is often measured by regression of tumors, not stasis of 
tumors. For example, radiation or chemotherapy, which trigger the DNA 
damage response, may be beneficial to combine with SRC inhibitors. Upon 
SRC inhibition, p53 will be more likely to be active and activate apoptotic 
pathways.  
 Inhibition of MDM2 in our cells that harbor wild-type p53 led to cell 
death likely due to apoptosis from active p53 (Jones et al., 1995; Montes de 
Oca Luna et al., 1995). In the experiments where we overexpressed mutated 
SRC phosphorylated tyrosines (Batuello et al., 2015) on MDM2 to be 
“unphosphorylated”, we showed a decreased growth rate, suggesting that the 
phosphosites are important for proliferation. To test the hypothesis that SRC 
functions via MDM2 to inhibit p53, experiments will have to be performed as to 
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not induce apoptosis. As was stated earlier in this thesis, decreasing the dose 
of MDM2 and possibly MDMX is required for cell survival, but may increase 
the likelihood of manipulating either MDM2 or MDMX to test for cell cycle 
regulators of p53. These studies are important to define a role for MDM2 in 
cell cycle regulation. 
Lastly, these studies were conducted in the ER-positive breast cancer 
cell lines, MCF7 and ZR-75-1, which have been almost exclusively used for 
the study of ER-positive breast cancer for years. These cell lines have 
provided invaluable insight into E2 signaling both in normal and cancerous 
cells, however, there are some questions about how generalizable are the 
findings in these cell lines. Several reports have also suggested that different 
sources of MCF7 cells have different responses to E2 as well as overall gene 
expression profiles (Nugoli et al., 2003; Osborne et al., 1987).  
New models of ER-positive breast cancer would greatly benefit the 
field, and could be used to confirm some of the findings in the MCF7 and ZR-
75-1 cells. Several studies have suggested that injection of ER-positive cells 
intraductally leads to tumors that better mimic the human disease, including 
ductal carcinoma in situ (DCIS) (Behbod et al., 2009; Valdez et al., 2011). For 
example, MCF7 cells transplanted into the mammary fat pad undergo gene 
expression changes that make the tumors more basal-like as compared to 
MCF7 cells injected intraductally which results in maintenance of a more 
luminal phenotype (Sflomos et al., 2016). 
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While the intraductal injections often still use established breast cancer 
cell lines, many groups are developing ER-positive patient derived xenografts 
(Kanaya et al., 2016; Matthews and Sartorius, 2017). These xenografts 
typically involve dissecting a biopsy sample and dissociating the cells. The 
cells are then grow in an immunocompromised mouse, and upon reaching a 
certain size, dissociated again and passaged into a new mouse. These 
models are attractive as new models of ER-positive breast cancer, however, 
the ER-positive xenografts tend not to graft as well as triple negative breast 
cancers. 
Genetically engineered mouse (GEM) models of breast cancer are 
incredibly useful tools to study many of the biological processes involved in 
cancer progression. Germline knockout mice can offer insight into initiation of 
spontaneous models of cancer. A variety of new conditional models are 
becoming available so that disruption of a gene can occur in both a tissue and 
time specific manner to study a variety of questions. While the mouse 
mammary tumor virus (MMTV)/Polyoma virus middle T antigen (PyVmT) 
breast cancer model is useful for studying SRC driven cancers, ER-positive 
tumors do not develop. Unfortunately for the ER-positive breast cancer 
research community, very few if any mouse models of breast cancer 
accurately recapitulate the human disease. Mouse models of ER-positive 
breast cancer that do exist, often have mutated or inactivated p53, express the 
ER at relatively low frequency, and typically have very long (10-24 months) 
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latency period before tumor development (Dabydeen and Furth, 2014; Mohibi 
et al., 2011). 
Better ER-positive model systems are required for use in future 
preclinical trials, particularly for testing the efficacy of SRC inhibitors. Several 
preclinical and clinical trials in breast cancer have suggested that inhibition of 
SRC using kinase inhibitors including dasatinib (Mayer et al., 2011; Mitri et al., 
2016) and bosutinib (Campone et al., 2012; Hebbard et al., 2011) resulted in 
stable disease in a fraction of the hormone receptor (HR)-positive cohort. We 
postulate that these patients expressed wild-type p53, however, expression 
was not analyzed in these studies. Based on this, we suggest that therapeutic 
inhibition of SRC may be effective in early stage ER-positive breast cancer 
expressing wild-type p53, and more generally, to cancers that retain wild-type 
p53. In addition to selecting patients for SRC inhibitor therapy based on p53 
status, we also suggest that the multi-targeted kinase inhibitors used to target 
SRC in the clinic may not have an appropriate selectivity for SRC. From this 
study, genetic inhibition of SRC in tumors that lack p53 did not regress, 
however, treatment of tumors with saracatinib led to regression of the tumors 
regardless of p53 status. This suggests that “off-target” effects of the inhibitor 
may complicate targeted treatment based on p53 status. SRC inhibition as a 
treatment strategy for patients will likely require the use of p53 status as a 
biomarker, and potentially, the generation of more selective SRC inhibitors for 
use in the clinic. 
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In conclusion, this study furthered our understanding of the non-
genomic E2 signaling pathway in ER-positive breast cancer. We found a 
mechanism by which SRC regulates gene expression by stabilization of 
mRNA rather than transcription after E2 stimulation. We also found a role for 
SRC in inhibiting p53 function and some suggestion that MDM2 may be 
mediating this function. In addition to understanding this mechanism, the E2-
SRC-p53 axis may also inform therapeutic decisions in the clinic. Our data 
suggest that patients who are ER-positive and retain wild-type p53 may benefit 
the most from SRC inhibitors. 
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In addition to my biomedical sciences-based thesis work, I also had the 
opportunity to conduct biology education research (BER). I have an interest in 
education and my long-term career goals involved teaching and running a 
research program at a primarily undergraduate institution. To this end I 
conducted BER research under the supervision of Dr. Ella Tour. Part II 
consists of two published manuscripts detailing this work where we used 
primary literature articles in a Master’s level course to test the effects on 
students’ science process skills, perceptions, and perceived difficulties with 
reading primary literature. 
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